 
Document Type:  Study Protocol  
Official Title:  A Study to Evaluate the Effectiveness of Essure Post -
NovaSure Radiofrequency  Endometrial Ablation Procedure 
Following a Successful Essure Confirmation Test  
NCT N umber:  [STUDY_ID_REMOVED]  
Document D ate: 12-Jul-2016  
 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 1of [ADDRESS_8179]
This protocol version is an integration of the following documents / sections:
Original protocol, Version 0, dated 22 DEC 2011
Amendment no. 1 (described in Section 13.1)
forming integrated protocol Version 1.0, dated 03 FEB 2012
Amendment no. 2 (described in Section 13.1)
forming integrated protocol Version 2.0, dated 15 FEB 2012
Amendment no. 3 (described in Section 13.1)
forming integrated protocol Version 3.0, dated 19 DEC 2012
Amendment no. 4 (described in Section 13.2)
forming integrated protocol Version 4.0, dated 12 DEC 2014
Amendment no. 5 (described in Section 13.3)
forming integrated protocol Version 5.0, dated 03DEC 2015
(approved by [CONTACT_8956] 12 MAY 2016)
Amendment no. 6 (described in Section 13.4)
forming integrated protocol Version 6.0, dated 12 JUL  2016
(approved by [CONTACT_8956] 29 SEP 2016)
Amendments not included in the consecutive numbering of amendments are 
local amendments not forming part of this integrated global protocol.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 2of [ADDRESS_8180] device : BAY 1454032
Study  purpose:The purpose of the study  is to evaluate the effectiveness and 
safet y of the Essure S ystem when a NovaSure endometrial 
ablation ( EA) procedure is performed following a successful 
Essure Confirmation Test.
Clinical study  phase: Post-approval study (PAS) Date: [ADDRESS_8181] no.: Not applicable Version no.: 6.0
Study  no.: [ZIP_CODE]   
Sponsor:Bayer HealthCare, LLC1
[ADDRESS_8182]
Whippany , NJ [ZIP_CODE]
[LOCATION_003]
Sponsor’s medical expert:[INVESTIGATOR_8998] ,LLC
[ADDRESS_8183]
[PO_BOX]
Whippany , NJ [ZIP_CODE] 
[LOCATION_003]Telephone: 
The study  will be conducted in compliance with the protocol, ISO [ZIP_CODE], ICH- GCP and an y 
applicable regulatory  requirements.
Confidential
The information provided in this document is strictly  confidential and is intended solely  for 
the guidance of the clinical investigation.  Reproduction or disclosure of this 
document - whether in part or in full - to parties not associated with the clinica l 
investigation, or its use for any other purpose, without the prior written consent of the 
sponsor is not permitted.
Throughout this document, symbols indicating proprietary names ( , TM) may not be displayed.  Hence, the 
appearance of product names with out these symbols does not imply that these names are not protected.
                                                
1Per Amendment 4 and 6
2Per Amendment 4
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 4of 82
Signature [CONTACT_9000]
[INVESTIGATOR_8911].
Name:
[CONTACT_1782]: Signature:
[CONTACT_9001][INVESTIGATOR_8912]’s study  file and in the respective 
center’s investigator site file.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 5of [ADDRESS_8184] (Essure- NovaSure PAS)
Short title Essure -NovaSure PAS
Clinical study phase Post-approval study (PAS)
Study objectives The objectives of this study are to:
Evaluate the contraceptive failure rate of Essure when NovaSure is 
performed following a succ essful Essure Confirmation Test, and
Monitor the incidence of adverse events and/or complications associated with the performance of NovaSure in the presence of Essure micro -
inserts.
Test device BAY 1454032 (Essure 305)
Indication The Essure®System is indicated for w omen who desire non -incisional 
permanent birth control (female sterilization) by [CONTACT_8957][INVESTIGATOR_2134].  The NovaSure endometrial ablation (EA) procedure is indicated for 
the treatment of menorrhagia.
Diagnosis and main criteria for 
inclusionSubject is betw een 21 -50 years of age
Subject is betw een 90 -300 lbs (40 -136 kg)
Subject has a successful Essure Confirmation Test showing bilateral 
satisfactory micro -insert location (when using transvaginal ultrasound 
[TVU]) or both bilateral satisfactory location and tubal occlusion (when 
using a modified hysterosalpi[INVESTIGATOR_8913] [HSG]) documented in her 
subject record.4
Subject is experiencing menorrhagia due to benign causes
Subject is willing to use NovaSure as endometrial ablat ion procedure for 
menorrhagia
Subject is willing to accept the risk of pregnancy while relying on the Essure micro -inserts for prevention of pregnancy following a NovaSure 
ablation procedure for menorrhagia
Subject is willing and able to give written Informed Consent prior to 
participation in the post -approval study, in accordance w ith regulatory 
requirements
Subject is willing and able to complete all follow -up visits as required 
by [CONTACT_7620] -approval study protocol
Subject is willing and able to allow  their data to be shared with the post-
approval study Sponsor, Inst itutional Review Board / Ethics Committee 
and the Food and Drug Administration of the [LOCATION_002] ( FDA )
                                                
3New  section from sponsor template; populated per Amendment 4.
4The definition of the Essure confirmation test modified per Amendment 6 to include transvaginal ultrasound.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 6of 82
Study design Prospective, multi -center, single- arm observational study
Methodology In this study, the NovaSure EA procedure following successful placement of 
a commercially available Essure device is the treatment being administered.  
The Essure device, with the exception of relatedness to adverse events (AE), 
and placement procedure are no t being evaluated.
One week (plus or minus two days) from the date of NovaSure EA, the 
subject w ill return to the physician’s office for a physical exam, to inquire 
whether or not any adverse events occurred since the NovaSure procedure and to conduct a su bject interview  to obtain information on subject 
satisfaction and comfort with wearing the Essure micro -inserts post -
NovaSure EA.
One, two -, and three- years (± 28 days) from the date of the NovaSure EA 
procedure, the subject w ill be contact[CONTACT_8958]’s office to have a 
telephone follow -up visit.  During each of these visits, designated study staff 
will conduct a subject interview to confirm subject is not currently pregnant 
or has not been pregnant in the previous year, to inquire whether or not a ny 
adverse events occurred over the past year, to obtain information on subject satisfaction and comfort with wearing the micro -inserts post -NovaSure EA 
procedure and to discuss whether or not subject has had or will have any 
extirpative surgery.
Type of control Not applicable
Number of subjects Approximately [ADDRESS_8185].
Plan for statistical analysis The primary effectiveness endpoint of this study is the 1 -year and 3 -year 
pregnancy rates.  The rates will be calculated as described below .
Each w oman-month of follow- up represents a “Ber noulli trial” of the Essure 
device.  A woman contributes as many women -months as her participation in 
the post -approval study.  Upon observing f failures in w women -months, the 
posterior distribution of the monthly failure rate, r, is calculated as:
r = b eta(a+f, b+w -f) 
where a and b = 0.5, representing a non -informative prior distribution.  The 
upper Bayesian credible interval of ris easily calculated from the inverse 
beta function.  A 1 -year failure rate can be calculated as:
1-year rate = 1 -(1-r)[ADDRESS_8186] 1 year of follow -up.  
As an additional related calculation, we will determine the 3 -year failure as:
3-year rate = 1 -(1-r)36
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 7of 82
Table of contents
Cover page of the integrated protocol .................................................................................... 1
Title pa ge -amended ................................................................................................................. 2
Signature [CONTACT_8152]’s medically responsible person ..................................................... [ADDRESS_8187] identification ..................................................................................................... 19
6.Treatment ......................................................................................................................... 19
6.1 Treatments to be administered ....................................................................................... 19
6.2 Identity  of study  treatment ............................................................................................. 20
6.3 Treatment assignment -amended .................................................................................. 20
6.4 Dosage and administration............................................................................................. 20
6.5 Blinding ......................................................................................................................... 20
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 8of [ADDRESS_8188]-study  therapy .......................................................................................................... 20
6.9 Prior and concomitant therap y....................................................................................... 20
7.Procedures and variables ............................................................................................... 21
7.1 Schedule of procedures .................................................................................................. 21
7.1.1 Tabulated overview .................................................................................................... 21
7.1.2 Timing of assessments ................................................................................................ 22
[IP_ADDRESS] Eligibility  and Screening Visit ( -30 day s) -amended ............................................. 22
[IP_ADDRESS] NovaSure EA Procedure (Day  0) ............................................................................ 22
[IP_ADDRESS] One-Week Post -NovaSure EA Office Visit (± 2 day s)........................................... 23
[IP_ADDRESS] One-, Two -and Three -Year Post -EA Phone Call (± 28 day s)- amended .............. 23
[IP_ADDRESS] Notification of Other Relevant Events .................................................................... 24
7.2 Population characteristics .............................................................................................. 24
7.2.1 Demographics ............................................................................................................. 24
7.2.2 Medical history ........................................................................................................... 24
7.3 Efficacy .......................................................................................................................... 24
7.4 Safety ............................................................................................................................. 25
7.4.1 Adverse events ............................................................................................................ 25
[IP_ADDRESS] Definitions............................................................................................................... 25
[IP_ADDRESS].1 Adverse event ....................................................................................................... 25
[IP_ADDRESS].2 Serious adverse event (SAE)- amended ............................................................... 25
[IP_ADDRESS].3 Medical Device Report (MDR) Reportable Event ............................................... 27
[IP_ADDRESS].4 Device deficiency  -amended ............................................................................... 27
[IP_ADDRESS].[ADDRESS_8189] - a mended ................... 28
[IP_ADDRESS] Classifications for adverse event assessment .......................................................... 28
[IP_ADDRESS].1 Seriousness ........................................................................................................... 28
[IP_ADDRESS].2 Severity ................................................................................................................ 28
[IP_ADDRESS].3 Causal relationship ............................................................................................... 29
[IP_ADDRESS].4 Outcome ............................................................................................................... 29
[IP_ADDRESS] Assessments and documentation of adverse events -amended .............................. 30
[IP_ADDRESS] Reporting of serious adverse events - amended ...................................................... 30
[IP_ADDRESS] Expected adverse events .......................................................................................... 32
7.4.2 Device removal –new section .................................................................................... 32
7.4.3 Pregnancies ................................................................................................................. 32
7.5 Other procedures and variables43................................................................................... 32
7.6 Appropriateness of procedures / measurements43.......................................................... 32
8.Statistical methods and determination of sample size ................................................. 32
8.1 General considerations ................................................................................................... 32
8.2 Analy sis sets .................................................................................................................. 33
8.3 Variables ........................................................................................................................ 33
8.4 Statistical and analy tical plans ....................................................................................... 33
8.4.1 Primary  Endpoint ........................................................................................................ 33
8.4.2 Secondary  Endpoint .................................................................................................... 34
8.5 Planned interim anal yses............................................................................................... 34
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 9of [ADDRESS_8190] information and consent.................................................................................... 3811.3 Publication policy .......................................................................................................... 38
11.4 Compensation for health damage of subjects / insurance .............................................. [ADDRESS_8191] .................................................................................................................... 39
13.Protocol amendments ...................................................................................................... 40
13.1 Amendments 1 through 3 ............................................................................................... 40
13.2 Amendment 4 ................................................................................................................. 40
13.2.1 Overv iew of changes .................................................................................................. 40
13.2.2 Changes to the protocol text ....................................................................................... 4113.3 Amendment 5 ................................................................................................................. 64
13.3.1 Overview of changes .................................................................................................. 64
[IP_ADDRESS] Modification 1: revision of exclusion criterion #4.................................................. 6413.3.1.2 Modification 2: revision of exclusion criterion #6.................................................. 6413.3.1.3 Modification 3: number of sites increase ................................................................ 64
[IP_ADDRESS] Modification 4: minor clarifications ....................................................................... 65
13.3.2 Changes to the protocol text ....................................................................................... 6513.3.2.1 Section 4 Study  design ............................................................................................ 65
[IP_ADDRESS] Section 5.1.2 Exclusion criteria ............................................................................... 65
[IP_ADDRESS] Section 7.2.2 Medical history .................................................................................. 66
[IP_ADDRESS] Section [IP_ADDRESS] Assessments and documentation of adverse events ....................... 66
[IP_ADDRESS] Section [ADDRESS_8192] ......................................................................................... 66
[IP_ADDRESS] Section 14 Appendices ............................................................................................ 67
13.4 Amendment 6 ................................................................................................................. 67
13.4.1 Overview of changes .................................................................................................. 67
[IP_ADDRESS] Modification 1: addition of the TVU as an approved method for Essure Confirmation Test ................................................................................................... 67
[IP_ADDRESS] Modification 2: definition of a successful Essure Confirmation test was clarified 68
[IP_ADDRESS] Modification 3: modification of the Bay er template language regarding 
withdrawal criteria ................................................................................................... 68
[IP_ADDRESS] Modification 4: information regarding the follow- up of adverse events was 
specified .................................................................................................................. 68
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 10of 82
[IP_ADDRESS] Modification 5: NovaSure device was included in the definition of the adverse 
device effect, device deficiency , failure and malfunction ....................................... 68
[IP_ADDRESS] Modification 6: definition of the unanticipated adverse device effect was modified 
for consistency ......................................................................................................... 69
[IP_ADDRESS] Modification 7: the definition of serious adverse event (SAE) was revised........... 6913.4.1.8 Modification 8: definition of [LOCATION_003]DE was clarified ............................................... 69
[IP_ADDRESS] Modification 9: perforations and potential allergy /hypersensitivity  to Essure 
inserts were added to the Important Medical Events and events of special interest 69
[IP_ADDRESS] Modification 10: instructions for the Investigator to assess whether an AE is an 
unanticipated adverse device effect were removed ................................................. 69
[IP_ADDRESS] Modification 11: addition of a new section reg arding device removal ................... 70
[IP_ADDRESS] Modification 12: minor edits and clarifications ...................................................... 70
13.4.2 Changes to the protocol text ....................................................................................... 7013.4.2.1 Title page ................................................................................................................. 70
[IP_ADDRESS] Synopsis .................................................................................................................. 71
[IP_ADDRESS] Section 2 Study  objectives ...................................................................................... 71
[IP_ADDRESS] Section 5.1.1 I nclusion criteria ................................................................................ 72
[IP_ADDRESS] Section 5.2.1 Withdrawal ........................................................................................ 72
[IP_ADDRESS] Section 6.3 Treatment assignment .......................................................................... 73
[IP_ADDRESS] Section [IP_ADDRESS] Eligibility  and Screening Visit ( -30 day s)...................................... 73
[IP_ADDRESS] Section [IP_ADDRESS] One -, Two -and Three -Year Post -EA Phone Call (± 28 days) ....... 74
[IP_ADDRESS] Section [IP_ADDRESS].1.[ADDRESS_8193] (ADE) ................................................... 74
[IP_ADDRESS] Section [IP_ADDRESS].1.[ADDRESS_8194] (UADE) .......................... 75
[IP_ADDRESS] Section [IP_ADDRESS].2 Serious adverse event (SAE)....................................................... 7513.4.2.12 Section [IP_ADDRESS].2.[ADDRESS_8195] ([LOCATION_003]DE) ........... 76
[IP_ADDRESS] Section [IP_ADDRESS].4 Device deficiency ........................................................................ 77
[IP_ADDRESS] Section [IP_ADDRESS].4.1 Device failure ........................................................................... 77
[IP_ADDRESS] Section [IP_ADDRESS].4.2 Device malfunction .................................................................. 77
[IP_ADDRESS] Section [IP_ADDRESS].[ADDRESS_8196] ............ 78
[IP_ADDRESS] Section [IP_ADDRESS] Assessments and documentation of adverse events ....................... 78
[IP_ADDRESS] Section [IP_ADDRESS] Reporting of serious adverse events ............................................... 79
[IP_ADDRESS] Section 7.4.2 Device removal ................................................................................. 8013.4.2.20 Section 8.6 Determination of sample size ............................................................... 80
[IP_ADDRESS] Section 14 Appendices ............................................................................................ 81
14.Appendices - amended ..................................................................................................... 82
15.Detailed Study Timelines ................................................................................................ 82
Table of tables
Table 7–1:  Schedule of Events................................................................................................ 21
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 11of [ADDRESS_8197] of abbreviations5-amended
ADE Adverse device event
ADL activities of daily living
AE Adverse event
CFR Code of Federal Register
CRF Case Report Form
D&C dilatation and curettage
EA Endometrial Ablation
ECG electrocardiogram
eCRF Electronic case report form
EMA European medicines evaluation agency
FDA Food and Drug Administration of the [LOCATION_002]
GCP Good clinical practices
HSG Hysterosalpi[INVESTIGATOR_8914]®
ICF Informed consent form
IEC Independent ethics committee
IFU Instructions for Use
IME Important medical events
IRB Institutional Review Board
IUD Intrauterine device
IUS Intrauterine system
IVRS Interactive voice response system
LPLV Last patient last visit
MDR Medical device report
PAS Post-Approval Study
PMA Pre-market Approval
SADE Serious adverse device e ffect
SAE Serious adverse event
TVU Transvaginal ultrasound
UADE Unanticipated adverse device e ffect
[LOCATION_003]DE Unanticipated serious adverse device effect
US [LOCATION_002]
                                                
5Revised per Amendment 4 and 6
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 12of 82
1. Introduction
1.1 Endometrial Ablation
Endometrial ablation (EA) has become a well- established treatment for pre -menopausal 
women with menorrhagia (excessive bleeding) and an alternative to h ysterectomy  for some 
patients.  Treatment for menorrhagia may  include hormone therap y, endometrial curettage, 
endometrial abl ation, and hy sterectom y.  Women who are opposed to hysterectom y and those 
for whom other treatment options were unsuccessful may consider EA rather than 
hysterectom y.  Traditional treatments for d ysfunctional uterine bleeding and menorrhagia 
include hormon e replacement therapy , dilatation and curettage (D&C) , and hy sterectom y.  EA 
and hy sterectomy  are offered as treatment options when medical therapy  and/or D&C fail.
1.[ADDRESS_8198] be finished with childbearing, EA should not be considered a means of sterilization.  Pregnancy  should not be elected after an ablation because 
it can be dangerous for both the fetus and mother; therefore, women need to ha ve a reliable 
contraceptive method if they  choose to undergo EA.  The Essure procedure is a hy steroscopic 
permanent sterilization method and a complement to various EA technologies.  Women who 
have undergone h ysteroscopic sterilization with the Essure proc edure may  become candidates 
for EA procedures should they  develop menorrhagia requiring treatment in the future .
[ADDRESS_8199] the effectiveness and safety  of Essure .7
1.3 Essure System
The Essure procedure is a non- incisional surgical procedure that involves placing a small, 
flexible device called a micro -insert into each fallopi[INVESTIGATOR_8915].  Besides the “space -filling” aspect of the 
micro- insert, the primary method of action consists of a benign tissue ingrowth that occurs 
after placement and occludes the fallopi[INVESTIGATOR_8916].  The Essure s ystem consists of the micro-
insert and a disposable delivery  system and has undergone clinical investigation sin ce 1996.  
The Essure s ystem received Food and Drug Administration (FDA) approval in 2002 
(P020014) and is commercially available in the [LOCATION_002], Europe (CE Mark approval received February  2001), Canada, Australia, and various Central/South American a nd Asian 
countries.
1.4 NovaSure Imped ance Controlled Endometrial Ablation System
The NovaSure procedure employ s radio frequency delivered via a bipolar electrode array  into 
the uterine cavity .  NovaSure received FDA approval in 2001 (P010013) for the indicati on of 
endometrial ablation in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete.  Though NovaSure is currently  labeled and contraindicated 
for use in “…a patient with a thermally conductive object (e.g. metal impla nt) present in the 
                                                
6Per Amendment 4
7Per Amendment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 13of [ADDRESS_8200] or 
close proximity  to the heat generation portion of the endometrial ablation device...”, clinical 
and commercial reports have demonstrated the sa fety of performing NovaSure EA with 
Essure micro- inserts in place (Section 1.5).
1.[ADDRESS_8201] been evaluated in both peri -
and pre -hysterectomy  clinical settings.  Coad, et al. conducted a feasibility  study  to evaluate 
tissue ingrowth viability  along the Essure micro -inserts’ length following NovaSure 
endometrial ablation.  In accordance with Essure’s I nstructions for Use, the study  subjects 
(n=6) underwent bilateral micro-insert placement greater than [ADDRESS_8202] and subsequent NovaSure endometrial ablation.  The study  demonstrated 
continued Essure micro -insert tissue ingrowth viability  within the distal interstitial/isthmic 
fallopi[INVESTIGATOR_8917].  No distal thermal tissue 
necrosis propagation, along the micro -inserts’ length, was identified outside the NovaSure 
ablation zone.  The proximal thermally injured micro -insert ingrowth within the ablation zone 
should heal in conjunction with the heal ing timeline for the NovaSure ablation.  The results 
support continued effectiveness of the Essure micro-inserts post- NovaSure ablation and 
confirm those of a prior reported peri -hysterectomy  feasibility  study [[1]].  Similarly , the 
Essure micro-inserts did not appear to a ffect the NovaSure endometrial ablation [ [2]].
Coad, et al,reported on a feasibility  study  to evaluate for fallopi[INVESTIGATOR_8918] -insert placement with either Hy dro Thermablator (HTA) or 
NovaSure endome trial ablation.  The Essure followed by  [CONTACT_8959] (n=13) 
underwent unilateral Essure micro- insert placement immediately  followed by  [CONTACT_8960].  The contralateral fallopi[INVESTIGATOR_8919].  The stud y demonstrated that 
the Essure micro -inserts did not alter performance of either endometrial ablation sy stems.  
NovaSure ablations showed limited thermal tubal injury  that was similar to that of the Hy dro 
Thermablator control tubes.  No serosal injury  was identified.  The study  resu lts support 
acceptable safet y profiles for both HTA and NovaSure following Essure micro -insert 
placement [ [1]],[[3]].
1.5.[ADDRESS_8203] to be performed 90 -days after micro -insert 
placement; most patients chose not to wait because of their desire for the NovaSure endometrial ablation to eliminate their excessive uterine bleeding sooner.  Two patients 
required replacement of the micro -insert at the time of the NovaSure procedure because the 
micro-insert was attached to the NovaSure instrument when it was withdrawn.  A second 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 14of 82
device was placed without difficulty .  At up to two y earsof follow up (for the earliest study  
participant), none of the study  subjects have had a pregnancy.  No complications occurred and 
no adverse events have required treatment or hospi[INVESTIGATOR_059] [[4]].
Basinski ,et al, conducted a retrospective review of 117 patients who had undergone Essure 
micro- insert placement followed by  [CONTACT_8961]- office sessions separated b y a median 
time of 14 day s.  In t his study , 83/117 (71%) returned for the Essure Confirmation Test.  
Satisfactory  placement and tubal occlusion was demonstrated in 79/83 (95%) of these 
patients.  Amenorrhea or spotting was observed in 72/97 (74%) of patients, 22/97 (23%) 
reported satisfac tory decrease in menstrual flow, and 3/97 (3%) patients reported failure of the 
ablation procedure.  A total of eight adverse events was obtained on 111/117 (95%) patients that had follow up.  None of the adverse events reported in the study  appeared to be related to 
the performance of NovaSure after Essure specifically .  There have been no reported 
pregnancies for the patients that have been rel ying on Essure for permanent contraception 
from 6 to 24 months.  The study results showed that the combination of Essure followed b y 
NovaSure did not decrease effectiveness of either procedure and no serious adverse events were attributed to the combination of the two procedures in this study [[5]].
1.5.[ADDRESS_8204] frequent adverse event that could be attributed to performing the two technologies together was the possibility of displacing or dislodging an implanted Essure micro -insert 
when performing NovaSure EA.  The l arger studies demonstrated that the Essure micro -
inserts did not alter performance of NovaSure EA.  The benefit of performing NovaSure EA in patients wearing the Essure micro -inserts outweighs the risk of the adverse events that are 
expected to occur.  Th isclinical study  will evaluate the ability  of Essure micro- inserts to 
maintain contraception following NovaSure EA, providing further data to assess the risk -
benefit ratio
8.
1.6 Regulatory and Commercial Labeling History
CE Mark approval was received in July  2008 for the addition of information to the Essure 
Instructions for Use (IFU) regarding the safe and effective performance of certain endometrial ablation procedures (including radio frequency  ablation) in patients with Essure micro- inserts 
in place.  U nited States FDA approval was received in February  [ADDRESS_8205] ( hysterosalpi[INVESTIGATOR_8913] [HSG ]at three months) . This 
post-approva l study  (PAS) is being conducted under FDA’s “Condition of Approval” in order 
to evaluate the Essure System after a NovaSure procedure is performed per the approved labeling changes.
                                                
8Per Amendment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 15of 82
Further details can be found in the IFU, which contains comprehensive inf ormation on the 
study  device9.
2. Study objectives -amended
The objectives of this study are to:
Evaluate the contraceptive failure rate of Essure when NovaSure is performed following a 
successful Essure Confirmation Test*, and
Monitor the incidence of adverse events and/or complications associated with the 
performance of NovaSure in the presence of Essure micro -inserts.
*Successful Essure Confirmation Test = satisfactory  bilateral micro -insert location and 
fallopi[INVESTIGATOR_8920], or sat isfactory  or optimal bilateral micro -insert 
location and retention in both tubal ostia when using transvaginal ultrasound ( TVU )(i.e. the 
subject is able to rely on Essure for contraception) . Note: all subsequent descriptions of 
"successful" Essure confirm ation test refer to this definition.10
3. Investigators and other study personnel11
Whenever the term ‘investigator’ is noted in the protocol text, it may  refer to either the 
principal investigator [INVESTIGATOR_8921], or an appropriately  qualified, trained and deleg ated 
individual of the investigational site.
Post-approval study  (PAS) sites and phy sicians will be selected in the [LOCATION_002] in major 
metropolitan areas to achieve an appropriate enrollment rate of post -approval study  subjects.  
Sites will be selected based on phy sician commercial experience with both the Essure Sy stem 
and NovaSure EA, and site/phy sician utilization rates thereof.
The principal investigator [INVESTIGATOR_8922].  Likewise, all protocol amendments/integrated 
protocols must be signed and dated by [CONTACT_458] [INVESTIGATOR_8923].
Acomplete list of all participating centers and their investigators, as well as all required 
signature [CONTACT_9002], will be maintained in the sponsor study  file.
All other study  personnel not included in this section are identified in a separate personnel list 
(not part of this clinical study  protocol) as appropriate.  This lis t will be updated as needed; an 
abbreviated version with personnel relevant for the centers will be available in each center’s 
investigator site file.
The global sponsor of this study  is identified on the title page of this protocol.   If required b y 
local law, local co -sponsors will be nominated; they  will be identified on the respective 
country -specific signature [CONTACT_1787].
                                                
9Per Amendment [ADDRESS_8206] was aligned w ith the IFU per Amendment 6.
11New  section from sponsor template per Amendment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 16of [ADDRESS_8207] 50% of the subjects enrolled in the study  must be [ADDRESS_8208] visit (L PLV). The end of the 
study  as a whole will be the date when the clean data base is available.
4.1 Primary variable
Occurrence of confirmed pregnancy  at [ADDRESS_8209].
4.2 Secondary variable
Adverse event data
5. Study population14
PAS sites and phy sicians will be selected in the [LOCATION_002] in major metropolitan areas to 
achieve an appropriate enrollment rate of post-approval study  subjects.  Sites will be selected 
based on ph ysician commercial experience with both the Essure Sy stem and NovaSure EA, 
and site/phy sician utilization rates thereof.
5.1 Eligibility
Candidates who are willing to participate in the study , meet the inclusion and exclusion 
criteria, and provide Informed Consent will be eligible for the study .  They will then be 
entered onto an Informed Consent L og.
                                                
12Per Amendment 5
13Per Amendment 4
14Section title was formerly Recruitment Strategy for the same content, changed per Amendment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 17of [ADDRESS_8210] is between 90 -300 lbs (40-136 kg)
3.Subject has a successful Essure Confirmation Test showing bilateral satisfactory
micro- insert location (when using transvaginal ultrasound [TVU] ) or both bilateral
satisfactory  insert location and tubal occlusion (when using a modified 
hysterosalpi[INVESTIGATOR_8913] [HSG]) documented in her subject record15  
4.Subject is experiencing menorrhagia due to benign causes
5. Subject is willing to use NovaSure as endometrial ablation procedure for menorrhagia
6.Subject is willing to accept the risk of pregnancy  while rel ying on the Essure micro-
inserts for prevention of pregnancy following a NovaSure ablation procedure for 
menorrhagia16
7. Subject is willing and able to give written Informed Consent prior to participation in 
the post -approval stud y, in accordance with regulatory  requirements
8. Subject is willing and able to complete all follow- up visits as required b y the post -
approval stud y protocol
9.Subject is willing and able to allow their data to be shared with the post -approval 
study  Sponsor, Institutional Review B oard / Ethics Committee and the FDA
5.1.[ADDRESS_8211] previously  underwent a fallopi[INVESTIGATOR_8924] (other than 
Essure placement)
2. Subject is pregnant or desires to become pregnant in the future3.Subject only  has one Essure micro -insert placed
4.Subject’s Essure Confirmation Test was performed less than three months (up to 1 
week prior to 3 months is considered acceptable) from the date of Essure placement
[ADDRESS_8212] has undergone any  intrauterine procedure in between Essure placement 
procedure and NovaSure EA. Endometrial biopsy  or sampling if r equired or indicated 
is permitted. Intrauterine device/ intrauterine sy stem ( IUD/IUS )removal is permitted. 
Procedures which permit direct visualization of the inserts while assessing the 
                                                
15TVU  confirmation testing criteria added per Amendment 6
16Per Amendment 4
17Per Amendment 5
18Per Amendment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 18of 82
endometrium to ensure that menorrhagia is due to benign causes (e.g. saline infusion 
sonograph y or diagnostic hysteroscopy ) are permitted [[6]][ADDRESS_8213] is scheduled to undergo an y other intrauterine procedures at the time of 
NovaSure EA (except endometrial biopsy or sampling , if required or indicated; 
IUD/IUS removal is permitted )[ADDRESS_8214] presents with any  other medical complaints, conditions or sy mptoms unrelated 
to the Essure Sy stem and/or subsequent NovaSure EA including, but not limited to: 
oGynecological co -morbidities (e.g., pelvic infection, cervicitis, undiagnosed 
vaginal bleeding, endometrial cancer, pre -malignant conditions of the 
endometrium, my omas, and poly ps)
oReproductive tract anatomical variants and/or pathology  which could make the 
subject unsuita ble for the Essure and/or NovaSure transcervical procedures 
(e.g. history  of previous classical cesarean section, transmural my omectomy , 
pathological condition that could lead to weakening of the m yometrium)
oActive genital or urinary  tract infection or pelvic inflammatory  disease at time 
of procedure
oAny other medical condition that precludes safe participation in the study , in 
the opi[INVESTIGATOR_8925]
9.Subject who has participated in another clinical study  in the [ADDRESS_8215] be withdrawn from the stud y for the following reasons:
At their own request or at the request of their legally acceptable representative
At any  time during the study  and without giving reasons, a subject may  decline to 
participate further.  The subject will not suffer an y disadvantage as a result.
If, in the investigator's opi[INVESTIGATOR_1649], continuation of the study  would be harmful to the 
subject's well -being
Subjects may  be terminated from the study  by [CONTACT_737].  Reasons for termination of a 
subject from the stud y may include, but are not limited to, the following:
Subject does not retain device (e.g.due to removal of device , expulsion, 
salpi[INVESTIGATOR_8926] -tubal surgeries)
                                                
19Per Amendment 4 and 5
20Per Amendment 4
21New  section from sponsor template per Amendment 4
22Withdraw al criteria adapted to suit a device meant for permanent wearing per Amendment 6.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 19of 82
Death
An adverse event ( AE)preventing study  participation
Lostto follow -up and inability  to contact [CONTACT_423].  Note that if a subject who is lost 
to follow -up is re-contact[INVESTIGATOR_530], the subject will not be considered to have withdrawn 
from the study .
A subject who discontinues study  participation prematurely  for any  reason is defined as a 
“dropout” if the subject has alread y undergone the NovaSure procedure.
A subject who, for an y reason (e.g. failure to satisfy the selection criteria), terminates the 
study  before the time point used for the definition of “dropout” (see above) is regarded a 
“screening failure”.
Any subject removed from the trial will remain under medical supervision until discharge or 
transfer is medically  acceptable.
In all cases, the reason for withdrawal must be recorded in the case report form ( CRF )and in 
the subject's medical records.Details for the premature termination of the study  as a whole (or components thereof 
[e.g. centers, treatment arms, dose steps]) are prov ided in Section 10(Premature termination 
of the study ).
5.2.[ADDRESS_8216] signed the informed consent form (I CF), they  will be identified by  a 
unique 5-digit subject identification number.  The subject identification number which will 
identify  the subject throughout the study  is constructed as follows:
Digit 1- 2:  Study  center number
Digit 3-5: Subject number, unique within any  study  center.  Sequential number 
reflecting the order in which the subjects signed the I CF at the center.
6. Treatment24
6.1 Treatments to be administered
In this stud y, the NovaSure EA procedure following successful placement of a commercially  
available Essure device is the treatment being administered.  The Essure device , with the 
exception of relatedness of AEs, and placement procedure are not being evaluated.
                                                
23New  section from sponsor template per Amendment 4.
24New  section from sponsor template (Section 6 populated with con tent from previous version of protocol) per 
Amendment 4.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 20of 82
6.2 Identity of study treatment
Not applicable.
6.3 Treatment assignment -amended
This is a non- randomized, continuous enrollment study in which all eligible subjects will be 
asked to enroll.  To avoid selection bias, investigators will offer enrollment in the study  to all 
eligible subjects consecutively  (as they  present themselves to the i nvestigator).
A subject may  not be enroll edin the study  until she has a successful Essure confirmation test 
done that documents bilateral satisfactory  device location and fallopi[INVESTIGATOR_8927] -insert location noted on TVU . If subject has had 
Essure placement but she does not have an Essure Confirmation Test that documents bilateral 
satisfactory  device location and fallopi[INVESTIGATOR_8928]- insert location onTVU , she may  repeat the Essure Confirmation Test .25
6.4 Dosage and administration
Not applicable.
6.5 Blinding
Blinding will not occur in this study . Procedures for emergency  unblinding are not required.
6.6 Device logistics and accountability
Not applicable.
6.7 Treatment compliance
The Essure device is intended for subjects who desire permanent contraception (female sterilization) an d is not intended to be removed .
6.[ADDRESS_8217]'s well- being will be 
allowed during the stud y.  Any  medical treatment administered for the treatment of AEs that 
occur during the stud y will be recorded in the CRF.
                                                
25TVU confirmation testing criteria added per Amendment 6
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 21of 82
7. Proced ures and variables
7.1 Schedule of procedures
7.1.1 Tabulated overview
Table 7–1 provides a tabulated overview of the study  schedule of procedures.
Table 7–1:  Schedule of Events
AssessmentsEligibility & 
Screening
(-30 days)NovaSure EA  
Procedure 
(Day 0)One-Week 
Post -EA 
Office Visit
(± 2 days)One-, Two -, and 
Three -Year Post -EA 
Phone Call
(± 28 days)
Informed Consent 
SignatureX
Inclusion / Exclusion CriteriaX X
a
Medical and 
Gynecologic HistoryX
Essure Confirmation 
Test Results ConfirmedX
Physical Exam and 
VitalsX X
Pelvic ExamX
Urine Pregnanc y TestXa
NovaSure ProcedureX
Pregnancy Status InquiryX
Adverse Event InquiryXbX X
Extirpative Surgery InquiryX
Subject InterviewX XbX X
Subject Contact [CONTACT_8962] X
bX X
Study Com pletion / Early 
Termination FormXc
Abbreviations:  EA = endometrial ablation
a  Assessment should be performed prior to NovaSure ablation
b  Assessment should be performed following NovaSure ablation
c  Complete the relevant form as necessary
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 22of 82
7.1.2 Timing of assessments
[IP_ADDRESS] Eligibility and Screening Visit ( -30 days) -amended
As would normally  occur, the subject will visit the phy sician seeking treatment for 
menorrhagia.  After the subject decides to undergo the NovaSure procedure, the phy sician or 
designated site staff will: 
Inform the subject of the Essure -NovaSure PAS.  Subject will not enroll in the study  
until she has a successful Essure confirmation test that documents bilateral satisfactory  
device location and fallopi[INVESTIGATOR_8929]- insert location noted on TVU .  If subject has had Essure placement but she does 
not have an Essure Confirmation Test that documents bilateral satisfactory device 
location and fallopi[INVESTIGATOR_8930] -insert 
location onTVU , she may  repeat the Essure Confirmation Test.26  
If subject is eligible, the phy sician or designated site staff will administer the Inf ormed 
Consent with the subject and answer an y questions the subject has.  
If subject agrees to proceed with the study , subject and phy sician or designated site 
staff will each sign and date the informed consent, and, the subject will receive a 
signed cop y.  
After having signed the Informed Consent (not before), subject will be asked all of the 
PAS I nclusion and Exclusion Criteria questions to verify  that subject is eligible for the 
study .  No study  procedures (including asking questions) will be done with out the 
subject having signed the I nformed Consent.  
The subject will then be asked a number of demographic and medical history  
questions.  
Subject will then undergo a brief ph ysical and pelvic exam.
If subject continues to meet screening criteria, the subject should be scheduled for the 
NovaSure EA procedure.
In order to minimize PAS loss to follow-up, during the Site Initiation visits, the sponsor’s
staff, or designee(s), will instruct the PAS I nvestigators and their respective Study  Staff to 
obtain the following subject information at Screening Visit: subject email addresses, both cell 
and home telephone numbers, and the same contact [CONTACT_8963] (e.g., spouse, sister, etc) and two close acquaintances.  They  will also be instructed to confirm 
contact [CONTACT_8964]/follow -up telephone call.  Thus, although the actual contact 
[CONTACT_8965] b y telephone, each PAS site will have multiple methods of contact[CONTACT_8966] a telephone contact.
[IP_ADDRESS] NovaSure EA Procedure (Day 0)
The Investigator or designated study  staff will confirm that the subject has not experienced an 
adverse event since the Eligibility and Screening Visit.  
                                                
26TVU confirmation testing criteria added per Amendment 6
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 23of 82
The NovaSure procedure will be performed in accordance with the NovaSure EA IFU and 
Controller Operator’s Manual.  
At the time of the procedure, subject’s uterine cavity  will be assessed to ensure that uterine 
cavity  length is not less than 4 cm and uterine cavity  width is not less than 2.5 cm(see 
Exclusion criteria 8; Section 5.1.2)27; if they  are, subject is ineligible to participate in the 
study .  
[IP_ADDRESS] One-Week Post-NovaSure EA Office Visit (± 2 days) 
One week (plus or minus two day s) from the date of NovaSure EA, the sub ject will return to 
the phy sician’s office.  At that time, designated study  staff will conduct the following 
assessments:
Physical Exam (Vitals)
Inquire whether or not any adverse events occurred since the NovaSure procedure 
Conduct subject interview to obtain information on subject satisfaction and comfort 
with wearing the Essure micro-inserts post-NovaSure EA
Confirm subject contact [CONTACT_3031] 
Discuss an y additional issues subject or the Investigator may have
[IP_ADDRESS] One-, Tw o-and Three-Year Post -EA Phone Cal l (± 28 days) -amended
One, two- , and three -years (± 28 days) from the date of the NovaSure EA procedure, the 
subject will be contact[CONTACT_8967]’s office to have a telephone follow -up visit.  During 
each of these visits, designated study staff wi ll conduct subject interview to:
Confirm subject is not currentl y pregnant or has not been pregnant in the previous year 
Inquire whether or not any adverse events occurred over the past year
Conduct subject interview to obtain information on subject sati sfaction and comfort 
with wearing the micro -inserts post- NovaSure EA procedure
Discuss whether or not subject has had or will have an y extirpative surgery
Confirm subject contact [CONTACT_3031] 
Discuss an y additional issues subject or the Investigator may ha ve
The [ADDRESS_8218] will be 
followed by  [CONTACT_456]’s pharmacovigilance department until event resolution or 
stabilization .  If a pregnancy  or serious adverse event was previousl y reported but the event is 
not resolved during the 3 -year phone call, the event will be followed by [CONTACT_456]’s 
                                                
27Per Amendment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 24of 82
pharmacovigilance department until resolution.  I nformation pertaining to these events will be 
collected and archived in the sponsor’s pharmacovigilance database.28
[IP_ADDRESS] Notification of Other Relevant Events
The subject should be instructed at the beginning of the study  to inform the site immediately  
if subject has had or is scheduled to have an y surgery  which may  remove some or all of her 
reproductive organs (i.e. hy sterectom y, salpi[INVESTIGATOR_8931] y)29.  
The subject will also be instructed to contact [CONTACT_8968] y if, at an y time 
during the st udy, subject thinks she might be pregnant.
If a subject experiences a micro-insert expulsion or removal during or following the NovaSure 
procedure, subject will be followed for the duration of the adverse event, then terminated from the study .
7.2 Population characteristics30
7.2.1 Demographics
Demographic data collected include, but may  not be limited to, date of birth (as allowed b y 
local law), race, and ethnicity .
7.2.2 Medical history
Medical history  findings ( i.e.previous diagnoses, diseases or surgeries) meeting all criteria 
listed below will be collected31:
Start before signing of the informed consent 
Considered relevant to the study .
Detailed instructions on the differentiation between (i) medical history  and (ii) adverse events 
can be found in Section [IP_ADDRESS].
7.[ADDRESS_8219].
                                                
28Follow -up of adverse events was specified per Amendment 6.
29Here, a sentence was deleted per Amendment 4 (please see Section 13.2 for details) .
30New  section from sponsor template (Section 7.2 populated with content from previous version of protocol) per 
Amendment 4 .
31“Not pertaining to the study indication” was deleted per Amendment 5 .
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 25of 82
7.4 Safety32
7.4.1 Adverse events
[IP_ADDRESS] Definitions
[IP_ADDRESS].[ADDRESS_8220] medical occurrence (i.e. any unfavorable and 
unintended sign [including a bnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study .  Therefore, an AE may  or may  not be temporally  or causally  associated with the use of 
a medicinal (investigational) product or device .
[IP_ADDRESS].1.[ADDRESS_8221] (ADE) -amended
An AE related to the use of Essure or Nova Sure, including AEs resulting from insufficient or 
inadequate instructions for use, deplo yment, implant (placement), installation or operation or 
any malfunction of the investigational medical device, use error or from intentional misuse of 
the medical device.33
[IP_ADDRESS].1.[ADDRESS_8222] (UADE)34-amended
A serious adverse effect is considered unanticipated if b y its nature, incidence, severity or 
outcome it has not been identified in the IFU.
[IP_ADDRESS].2 Serious adverse event (SAE)35-amended
An SAE is classified as any  untoward medical occurrence that, at an y dose, meets an y of the 
following criteria (a –g):
a.Results in de ath
b.Is life -threatening
The term ‘life -threatening’ in the definition refers to an event in which the subject was 
at risk of death at the time of the event, it does not refer to an event which hypothetically  might have caused death if it were more severe.
                                                
32New  section headings from sponsor template (Section 7. 4populated w ith content from previous version of 
protocol) per Amendment 4
33NovaSure added per Amendment 6.
34  Per Amendment 4:  The definition of UADE used in protocol version 3.0 (Conceptus) is consistent with the 
definition of [LOCATION_003]DE in this protocol version (4.0).  The definition of UADE in this protocol version (4.0 ) only 
applies to non -serious events. This is corrected in Amendment 6 in accordance with 21 CFR 812.3(s).
35The definition of serious adverse event (SAE) w as updated per Amendment 6.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 26of [ADDRESS_8223] one of the following exceptions is met:
-The admission results in a hospi[INVESTIGATOR_8932] 12 hours
- The admission is pre- planned
(e.g. elective or scheduled surgery  arranged prior to the start of the study ; 
admission is part of the study  procedures as described in Section 7.1.2)
-The admission is not associated with an AE (e.g. social hospi[INVESTIGATOR_8933]).
However, it should be noted that invasive treatment during an y hospi[INVESTIGATOR_8934] c riterion of ‘medicall y important’ and as such may be reportable as an SAE 
dependent on clinical judgment.  In addition, where local regulatory  authorities 
specificall y require a more stringent definition, the local regulation takes precedence.
d.Results in persistent or significant disability  / incapacity
Disability  means a substantial disruption of a person’s ability  to conduct normal life’s 
functions.
e.Is a congenital anomal y / birth defect
f.Is another serious or important medical event as judged b y the investigator 
g.Requires intervention to prevent permanent impairment of a bod y function /damage , to 
a body  structure
Note:   For the purposes of this protocol, ectopic pregnancy  and spontaneous abortion are 
alway s considered as important events and therefore reported as SAEs.
[IP_ADDRESS].2.1 Incident
Any malfunction or deterioration in the characteristics and / or performance of a device, as 
well as an y inadequacy in the labeling or the instructions for use which, directly or indirectl y, 
led to, might lead to or might have led to the death of a patient, or user or of other persons or to a serious deterioration in their state of health.
Any event which meets all three basic reporting criteria (A-C) is considered an Incident:
A.An event has occurred, e.g.• malfunction or deterioration in the characteristics or performance
• unanticipated adverse reaction or unanticipated side effect
• interactions with other substances or products
• degradation / destruction of the device• inappropriate therap y
• inaccuracy  in the labeling, instructions for use including omissions or 
deficiencies
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 27of 82
B) The device is suspected to be a contributory  cause of the incident.
C) The event led, or might have led, to one of the following outcomes:
•death of a patient, or user, or other person
•serious deterioration in state of health of a patient, user or other person
(See European Commission, Medical Devices: Guidance document MEDDEV 2.12-1)
[IP_ADDRESS].2.[ADDRESS_8224] ([LOCATION_003]DE) -amended
An unanticipated serious adverse device effect (U SADE) is an y serious adverse effect on 
health or safety  or any  life-threatening problem or death caused by , or associated with, a 
device, if that effect, problem, or death was not previously  identified in nature, severity , or 
degree of incidence in the investigational plan or application (including supplementary  plan or 
application), or an y other unanticipated serious problem associa ted with a device that relates 
to the rights, safet y, or welfare of subjects. This is the same definition provided in the UADE 
Section [IP_ADDRESS].1.2. This has been corrected above in the UADE definition. However, as both 
terms have been used at various timepoints in this protocol, the definition is maintained 
here.36
[IP_ADDRESS].3 Medical Device Report (MDR) Reportable Event
(1)An event that user facilities become aware of that reasonabl y suggests that a device has or 
may have caused or contributed to a death or serious injury ; or
(2)An event that manufacturers or importers become aware of that reasonabl y suggest that 
one of their marketed devices:
(i) May have caused or contributed to a death or serious injury , or
(ii) Has malfunctioned and that the device or a similar device marketed b y the 
manufacturer or importer would be likely  to cause or contribute to a death or 
serious injury  if the malfunction were to recur.
(See 21 CFR 803 M edical Device reporting)
An MDR corresponds to the definition of Incident.
[IP_ADDRESS].4 Device deficiency -amended
Inadequacy  of Essure or Novasure related to its identity , qualit y, durability, reliability, safet y 
or performance, such as malfunction, misuse or use err or and inadequate labeling.33
[IP_ADDRESS].4.1 Device failure -amended
Failure of Essure or Novasure to perform or function as intended, including an y deviations 
from the performance specifications or intended use (e.g., pregnancy  when micro -insert 
properl y located and fallopi[INVESTIGATOR_8935]; continued menorrhagia despi[INVESTIGATOR_040] a completed 
endometrial ablation procedure) . For the purposes of this study , a pregnancy  that occurs in a 
subject told to rely  on a commercially  available Essure devi ce for contraception is a device 
                                                
36Modified per Amendment 6, see Section [IP_ADDRESS].1.2 UADE.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 28of 82
failure. For the purposes of this protocol, persistence or recurrence of heavy menstrual 
bleeding will be considered device failures for the Novasure device.33
[IP_ADDRESS].4.2 Device malfunction -amended
Failure of Essure or Novasure to meet its performance specifications or otherwise perform as 
intended when used in accordance with the IFU (e.g., difficulties with deploy ment or 
detachment of micro-insert; device difficulties when conducting endometrial ablation).33
[IP_ADDRESS].[ADDRESS_8225] - amended
The Important Medical Events (IME) list is developed and published by  [CONTACT_8969]  (EMA )(http://eudravigilance.ema.europa.eu/human/textforI ME.asp).  All 
AEs reported in this study will be reviewed against the most current IME list periodically , and 
any events that are contained on the IME list will be specifically  reviewed and the 
Investigat or will be asked to review and confirm whether or not the event meets the criteria 
for seriousness in his/her opi[INVESTIGATOR_1649]. In addition, the following events of special interest will be 
closely  reviewed by  [CONTACT_456]’s study  medical expert:
Perforations of the uterus, cervix or fallopi[INVESTIGATOR_2134].37
Upper genital tract infections (for example: endometritis, salpi[INVESTIGATOR_8936] -oophoritis, 
salpi[INVESTIGATOR_8937]).
Expulsion or migration of Essure inserts.
Potential allergy /hypersensitivity  to Essure inserts (for example: itch [pruritus], rash, 
hives [urticaria] , facial edema, angioedema, allergy  to metals).37
[IP_ADDRESS] Classifications for adverse event assessment
All AEs will be assessed and documented by [CONTACT_8970]. 
[IP_ADDRESS].[ADDRESS_8226] be determined according to the criteria given in 
Section [IP_ADDRESS].
[IP_ADDRESS].2 Severity
The severit y of an AE is classified according to the following categories:
-Mild : asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated. 
-Moderate : minimal, local, or noninvasive intervention indicated; limiting age 
appropriate instrumental activities of daily  living (ADL).
-Severe : or medicall y significant but not immediately life threatening –hospi[INVESTIGATOR_8938], disabling; limiting self -care ADL .
                                                
37Added per Amendment 6.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 29of 82
[IP_ADDRESS].3 Causal relationship 
The assessment of the causal relationship between an AE and the administration of treatment 
is the investigator’s responsibility , and is a clinical decision based on all available information 
at the time of the completion of the CRF.  The assessment is based on the question of whether 
there was a “reasonable causal relationship” to the study  treatment in question.
The following information must be entered on the CRF for all AEs and SAEs:
Relation to the Essure device
Relation to the NovaSure device
Relation to the NovaSure procedure
Relation to a pre -existing condition (additional description required)
Possible choices for causality  include:
Not related
Unlikely  to be related
Possibly  related
Probably  related
Definitely  related
Important factors to be considered in assessing the relationship of the AE to the device or procedure include:
-The temporal sequence from the Essure placement procedure:  The event should occur 
after the procedure .  
-Underlying, concomitant, intercurrent diseases:  
Each event should be evaluated in the context of the natural history  and course of the 
Essure procedure and any other medical conditions the subject may  have.
-Concomitant medication or procedures: Any drugs t he subject is taking or additional procedures the subject receives should be 
examined to determine whether an y of them may  be suspected to cause the event in 
question.
[IP_ADDRESS].4 Outcome
The outcome of the AE is to be documented as follows: 
Recovered without treatme nt
Recovered with treatment
Not recovered with permanent impairment
Death
Undetermined, describe:
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 30of 82
[IP_ADDRESS] Assessments and documentation of adverse events38-amended
Investigators must collect all AEs for each subject from the time of signing of the informed 
consen t through the end of subject study  participation, whether or not deemed related to the 
investigational device or procedure.  All AE data will be recorded on the CRFs as well as documented in the subject’s medical record and study  source documents .
[ADDRESS_8227] determine whether adverse event meets the definition of a s erious adverse 
event; if so, it must be reported as required b y Section [IP_ADDRESS].
Any SAE or incident will be reviewed and processed by [CONTACT_8971].  Investigators must document all device failures, malfunctions and use errors, including the 
assessment ofwhether the event is considered a nincide nt (ADE) using the Device 
Malfunction and Failure CRF.
Because an approved device will be used for the placement procedure, an y device 
malfunctions will be reported to the sponsor’s Product Surveillance department.   Device 
malfunctions will not be anal yzedas part of this study  as the placement procedure and device s
are not being evaluated.
[IP_ADDRESS] Reporting of serious adverse events -amended
The definition of serious adverse events (SAEs) is given in Section [IP_ADDRESS].  These include 
device deficiencies that may  have led to a SAE if a) suitable action had not been taken or b) 
intervention had not been made or c) if circumstances had been less fortunate.  These are 
handled under the sponsor’s SAE reporting s ystem.
Investigator’s notification of the sponsor
All investigators will be thoroughly instructed and trained on all relevant aspects of the 
investigator’s reporting obligations for SAEs.  This information, including all relevant contact 
[CONTACT_8972], is summarized in the investigator site file.  This information will be updated as needed.
All SAEs and SADEs occurring during the observation period defined in Section [IP_ADDRESS] must 
immediately  (within 24 hours of the investigator’s awareness) be reported to the sponsor .
[ADDRESS_8228] also be completed within 24 hours of the investigator awareness and 
forwarded to the sponsor’s designated recipi[INVESTIGATOR_841].  Each SAE and incident must be followed up until resolution or stabilization by  [CONTACT_8973][INVESTIGATOR_841].  An y SAE or incident occurring after the protocol-
defined observation period will be processed by [CONTACT_8974].
                                                
38Section was updated per Amendment 6. 
39Per Amendment 5
40Sentence modified per Amendment 6.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 31of [ADDRESS_8229] s be considered as SAEs and 
reported as such to the Sponsor
Notification of the independent ethics committee ( IEC)s / institutional review board 
(IRB)s
Notification of the IECs / I RBs about all relevant events (e.g. SAEs, incidents, UADEs, 
device failures, device malfunctions) will be performed by [CONTACT_8975].
Notification of the authorities
The processing and reporting of all relevant events (e.g. SAEs, incidents, UADEs, device 
failures, device malfunctions) to the authorities will be done b y the sponsor according to all 
applicable regulations.
Because this is a PAS, the Essure S ystem is subject to Medical Device Reporting (MDR) 
regulations.  The sponsor will review all serious adverse events and unanticipated adverse 
device effects and determine their reportabilit y to FDA according to 21 Code of Federal 
Regulations 803 " Medical Device Reporting "   Reporting MDRs to FDA is r equired when the 
sponsor becomes aware of information that reasonably  suggests that a marketed device has or 
may have caused or contributed to a death, serious injury  or long -term pain necessitating 
surgical intervention, or has malfunctioned, and that the device or a similar device marketed 
by [CONTACT_8976] a death or serious injury  if the 
malfunction were to recur.  In the event information is received that the NovaSure Sy stem 
may have caused or may  have contribut ed to a death or serious injury , the sponsor will notify  
the complaint handling function of the manufacturer of the device (Hologic, Inc.).
Sponsor’s notification of the investigational site
The sponsor will inform all investigational sites about reported relevant events (e.g. SAEs 
incidents, UADEs, device failures, device malfunctions) according to all applicable 
regulations.
If the adverse event is the result of an unanticipated adverse device effect, the investigator 
must report it to the sponsor within 3 working days after the investigator becomes aware of 
the event.41  The investigator will send to the sponsor all pertinent paperwork (discharge 
summaries, office notes, etc.) within [ADDRESS_8230]’s subsequent medical co urse must be submitted to the sponsor 
until the event has subsided or, in case of permanent impairment, until the event stabilizes and 
the overall clinical outcome has been ascertained.  The investigator must report it to the Ethics 
Committee / I RB within the required time frame.
                                                
41Wording modified per Amendment 6.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 32of 82
[IP_ADDRESS] Expected adverse events
For this medical device study , the applicable reference document is the most current version 
of the IFU.
The expectedness of AEs will be determined b y the sponsor according to the applicable 
reference docume nt and according to all local regulations.
7.4.2 Device removal42–new section
Each time a removal procedure is performed, additional information will be collected about 
the circumstances surrounding the removal (reason for removal, procedure details, any  energy
sources used, vasoconstrictive agent used, imaging to assist with confirming the location of the insert, and the location and status of the device removed).
7.4.[ADDRESS_8231]’s participation in this study .  The report should be submitted within the same 
timelines as an SAE, although a pregnancy per se is not considered an SAE.
For a stud y subject, the outcome of the pregnancy should be followed up carefull y, and an y 
outcome of the mother or the child should be reported.  For all reports, the forms provided are 
to be used.
7.5 Other procedures and variables43
Not appli cable.
7.6 Appropriateness of procedures / measurements43
Not applicable.
8. Statistical methods and determination of sample size
8.[ADDRESS_8232] 
deviations, medians and ranges.  Categorical data will be summarized using frequency  rates 
(e.g., count/sample size).
                                                
42Section added per Amendment 6.
43Per Amendment 4
44Per Amendment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 33of 82
8.2 Analysis sets45
Primary effectiveness cohort
All subjects who meet study  entry  criteria, sign a study -specific ICF, and undergo i nsertion of 
the NovaSure device transcervically .
Primary safety cohortAll subjects in whoma NovaSure procedure is attempted .
8.3 Variables46
Primary:  Occurrence of confirmed pregnancy  at [ADDRESS_8233].
Secondary: Adverse event data
8.4 Statistical and analytical plans
8.4.1 Primary Endpoint
The primary  effectiveness endpoint of this study  is the 1 -year and 3- year pregnancy  rates.  
The rates will be calculated as done in prior Essure studies, as described below.
Each woman -month of follow -up represents a “Bernoulli trial” of the Essure device.  A 
woman contributes as many  women -months as her participation in the post- approval stud y.  
Upon observing f failures in w women- months, the posterior distribution of the monthly  
failure rate, r, is calculated as:
r = beta(a+f, b+w -f) 
where a and b = 0.5, representing a non- informative prior distribution.  The upper Bay esian 
credible interval of r is easily calculated from the inverse beta function.  A 1 -year failure rate 
can be calculated as:
1-year rate = 1- (1-r)[ADDRESS_8234] 1 y ear 
of follow -up.  
As an additional related calculation, we will determine the 3- year failure as:
3-year rate = 1- (1-r)36
For example, if there are 0 failures in 200 × 12 = 2,400 women-months, the posterior 
distribution of the monthly  failure rate is beta(0.5, 0.5 + 2400).  The upper Bay esian credible 
interval is (in Excel) betainv (.975, 0.5, 0.5 + 2400) = 0.[ZIP_CODE].  The upper 95% credible 
                                                
45New  section from sponsor template per Amendment 4
46New  section from sponsor template; populated with text from previous version per Amendment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 34of 82
interval for the 1 -year rate is 1- (1-0.[ZIP_CODE])12= 0.0125 or 1.25%47.  This value meets the pre-
determined stud y success threshold of 2.1%.  
8.4.[ADDRESS_8235] two y ears of the PAS, an interim PAS status report will be submitted every  
6 months from the date of the pre-market approval ( PMA )letter or other negotiated starting 
date (i.e., PAS initiation).  Ong oing interim PAS status reports will be submitted annually , 
thereafter, until the final PAS report is written after the termination or completion of the PAS.  
The ongoing interim reports and final PAS report will include information related to PAS methodol ogy and results/endpoints .
8.[ADDRESS_8236] and to demonstrate that the failu re rate is reasonably low (see details below).  Consistent with prior 
Essure clinical studies, a Bay esian approach will be used.  The study  will be considered a 
success if the posterior probability  (PPr) that the observed failure rate at 1 year (rate1 y) is
<2.1% is at least 95%, i.e.: 
PPr(rate1 y < 0.021) > 0.95 *
* 
i.e., a Type 1 error rate of 5%
If the posterior probability that the 1 -year rate is <0.021 exceeds 95%, we have shown with a 
high degree of confidence that the rate is at least as good as tha t which FDA has found 
acceptable for Adiana Permanent Contraceptive (PMA P070022).
Assumptions
The following assumptions were used to calculate the PAS sample size and power for the 1 -
and 3- year h ypothesis:
Participants in this PAS are women who have unde rgone the Essure procedure 
followed b y a successful Essure Confirmation Test showing satisfactory micro -insert 
location and bilateral tubal occlusion onHSG OR optimal or satisfactory  micro insert 
location onTVU ;48
Contraceptive failure rates after Essure are very  low for the PAS population as 
demonstrated b y prior clinical studies;
For the purposes of power calculations, the one -year pregnancy  rate is modeled as 
r=beta(0.5+a, 0.5+b), where beta(0.5,0.5) is a non -informative prior and a=0, b=600, 
                                                
47Per Amendment [ADDRESS_8237] ing criteria added per Amendment 6
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 35of 82
roughl y the size of the Essure Phase II and Pi[INVESTIGATOR_8939];
Multiple clinical trials are simulated with the underlying pregnancy  rate of r;
The one -sided upper Bayesian credible interval of the observed one -year failure rate 
amongst n=200 is calculated in 5000 simulated clinical trials using an underly ing 
pregnancy  rate of r;
Power for the 1 -year h ypothesis is the probability  that the Upper Confidence Limit of 
the 1- year rate is <2.1%, where 2.1% is the Upper Confidence Limit of the Adiana 
1-year failure rate (Table 5: Contraceptive Failure Rates, Adiana Permanent 
Contraception Instructions For Use, AW -[ZIP_CODE]- 001 Rev. 003);
Power for the 3 -year h ypothesis is the probability  that the Upper Confidence Limit of 
the 3- year rate is <2.8%, the Upper Confidence Limit of the Adiana 3 -year failure rate 
(Table 5: Contraceptive Failure Rates, Adiana Permanent Contraception Instructions 
For Use, AW -[ZIP_CODE]- 001 Rev. 003).
Given the assumed underly ing failure rate for a successful Essure procedure followed by  a 
confirmatory  Essure Confirmation Test, a study  of n=200 women has an 86% chance of 
showing that the Upper Confidence Limit of the 1 -year failure rate will be <2.1%.  The table 
below shows detailed results.
Expected number of
failures at [ADDRESS_8238] will be used at the site to identify the source data for all data points collected a nd the monitor will work with the site to complete this.
Data recorded from “only screened subjects (screening failures)”
Data of 'onl y screened subjects' will be recorded at least as source data, as far as the reason for 
the premature discontinuation is i dentifiable.  At minimum, data to be recorded in the CRF 
are demographic information (subject number, date of birth/age, sex, race and ethnicity ), the 
                                                
49All of Section 9 is a new section from sponsor template; populated according to sponsor guidelines per 
Amendment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 36of [ADDRESS_8239] visit :
All information about the SAE
All information related to the SAE such as: 
Concomitant medication
Medical history
Other information needed for SAE complementary  page
9.2 Monitoring
In accordance with applicable regulations, Good Clinical Practices ( GCP ), and sponsor’s 
procedures, monitors will contact [CONTACT_8977] y to review with the site 
staff the protocol, study requirements, and their responsibilities to satisfy regulatory, ethical, 
and sponsor’s requirements. When reviewing data collection procedures, the discussion will 
also include identification and documentation of source data items.
Thesponsor /designee will monitor the site activity  to verify  that the:
Data are authentic, accurate and complete
Safety  and rights of subjects are being protected
Study  is conducted in accordance with the currently  approved protocol 
(including stud y treatment being used in accordance with the protocol)
Any other study  agreements, GCP, and all applicable regulatory requirements are met.
Theinvestigator and the head of the medical institution (where applicable) agree to allow the 
monitor direct access to all relevant documents.
9.3 Data processing
The data collection tool for this study  will be via electronic CRF (eCRF) .  Subject data 
necessary  for anal ysis and reporting will be entered/transmitted into a validated database or 
data sy stem.  Clinical data management will be performed in accordance with applicable 
sponsor’s standards and data cleaning procedures.  This is applicable for data record ed on 
CRF as well as for data from other sources.For data coding (e.g.AEs), internationally  recognized and accepted dictionaries will be used.
9.4 Audit and inspection
To ensure compliance with GCP and regulatory  requirements, a member of the sponsor’s 
quali ty assurance unit may  arrange to conduct an audit to assess the performance of the study  
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 37of 82
at the study  site and of the study  documents originating there.  The investigator/institution 
will be informed of the audit outcome.
In addition, inspections by [CONTACT_8978](s)/I RB(s) are 
possible.  The investigator should notify  the sponsor immediately  of any  such inspection.
The investigator/institution agrees to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the time of his/her staff to the auditor/inspector to 
discuss findings and an y issues.  Audits and inspections may  occur at any  time during or after 
completion of the study .
9.[ADDRESS_8240] that ensures that they  
are readil y available upon authorities’ request.
Subject (hospi[INVESTIGATOR_307]) files will be archived according to local regulations and in accordance with 
the maximum period of time permitted by  [CONTACT_5035][INVESTIGATOR_307], institution or private practice.  Where 
the archiving procedures do not meet the minimum timelines required b y the sponsor, 
alternative arrangements must be made to ensure the availability  of the source documents for 
the required period.
The investigator/institution notifies the sponsor if the archival arrangements change ( e.g.
relocation or transfer of ownership).The investigator site file is not to be destroyed without the sponsor’s approval.
The contract with the investigator/institution will contain all regulations relevant for the stud y 
center.
10. Premature termination of the study50
The sponsor has the right to c lose this study  (or, if applicable, individual segments thereof 
[e.g.treatment arms; dose steps; centers]) at an y time, which may be due but not limited to the 
following reasons: 
If risk -benefit ratio becomes unacceptable owing to, for example,
-Safety  findings from this study  (e.g.SAEs)
-Results of any  interim analy sis
- Results of parallel clinical studies
If the stud y conduct ( e.g.recruitment rate; drop -out rate; data qualit y; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable time 
frame.
The investigator has the right to close his/her center at an y time.
                                                
50Section 10is a new section from sponsor template; populated according to sponsor guidelines per Am endment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 38of 82
For an y of the above closures, the following applies:
Closures should occur only  after consulta tion between involved parties.   Final decision 
on the closure must b e in writing.
All affected institutions ( e.g.IEC(s)/IRB(s); competent authority (ies); study  center ; 
head of stud y center ) must be informed as applicable according to local law.
All study  materials (except documentation that has to remain stored at site) must be 
returned to the sponsor.  The investigator will retain all other documents until 
notification given b y the sponsor for destruction.
In case of a partial study  closure, ongoing subjects, including those in post study  
follow -up, must be taken care of in an ethical manner.
Details for individual subject's withdrawal can be found in Section 5.2.1.
11. Ethical and legal aspects51
11.[ADDRESS_8241] (IRB) or Ethics Committee (EC) before study  commencement.  
Additionally , all sites will be monitored in accorda nce with Good Clinical Practices (GCP), 
US medical device regulations , the I nformed Consent provisions of the Declaration of 
Helsinki, and I SO [ZIP_CODE]: Clinical investigation of medical devices for human subjects –
Good clinical practice.  The study  will be registered in accordance with worldwide regulatory  
requirements.
11.[ADDRESS_8242]’s designated number in the Study  Binder.
11.[ADDRESS_8243] between the sponsor and 
the investigator/institution.
The sponsor has made the information regarding the study  protocol publicly  available on the 
internet at www.clinicaltrials.gov .  
                                                
51Section 11is a new section from sponsor template; populated according to sponsor guidelines and text from 
previous version of protocol per Amendment 4
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 39of 82
11.4 Compensation for health damage of subjects / insurance
The sponsor maintains clinical trial insurance coverage for this study  in accordance with the 
laws and regulations of the country  in which the study  is performed.
11.[ADDRESS_8244] will be kept confidential and, to the extent permitted by  [CONTACT_3999]/or regulations, will not be made publicly available.
Subject names will not be supplied to the sponsor.  Only the subject number will be recorded 
in the CRF, and if the subject name [CONTACT_9003] ( e.g.pathologist report), it 
must be obliterated before a copy of the document is supplied to the sponsor.  Study findings stored on a computer will be stored in accordance with local data protection laws.  As part of 
the informe d consent process, the subjects will be informed in writing that representatives of 
the sponsor, IEC/I RB, or regulatory  authorities may  inspect their medical records to verify  the 
information collected, and that all personal information made available for inspection will be 
handled in strictest confidence and in accordance with local data protection laws.
If the results of the stud y are published, the subject’s identity  will remain confidentia l.
The investigator will maintain a list to enable subjects to be identified.
12. Reference list52
[1].Coad JE , Garza -Leal J, Castillo -Saenz L ,et al. Essure permanent birth control 
followed b y global endometrial ablation: an in vivo peri -hysterectom y study. J Minim 
Invasive Gy necol. 2010;17(suppl):S39- S40.
[2].Coad JE , Garza -Leal J, Hernandez -Leon I, et al. Essure contraception followed b y 
NovaSure endometrial ablation: preservation of viable tissue in- growth after ablation. 
J Minim I nvasive Gy necol. 2011 Jul- Aug;18(4):445-448.
[3].Garza -Leal J, Hernandez -Leon I, et al. Essure transcervical sterilization combined 
with NovaSure endometrial ablation: a peri -hysterectomy  safet y stud y. J Minim 
Invasive Gy necol. 2008;15:44S.
[4].Saunders D. Essure and endometrial ablation: clinical studies and case reviews of 
Essure with 118 NovaS ure procedures. OBG Management. 2010;22([ADDRESS_8245]):S1- S8.
[5].Basinski CM, Price P, Burkhart J, Johnson J. Safety  and effectiveness of NovaSure 
endometrial ablation after placement of Essure micro- inserts. J Gy necol Surg. 
2012;28(2):83 -88.
[6].ACOG Practice Bulletin .Clinical management guidelines for obstetrician -
gynecologists. Number 81, May  2007. Obstet Gy necol . 2007;109(5):1233- 48.53
                                                
52Section 12is a new section from sponsor template; populated according to sponsor guidelines per Am endm ent 
4
53Added per Amendment 5
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 40of [ADDRESS_8246] 50% of subjects in the age range ≤ 45.  
Added Abbreviations table, Risk Analy sis 
summary , Adverse Event definitions, and 
Investigator Responsibilities section.  Modified protocol organization and individual sections layout to facilitate use by [CONTACT_8979].  Made other 
minor revisions to provide clarity and ease -of-
use. December 19, 2012
13.2 Amendment 4
Amendment 4 was approved by  [CONTACT_8956] 12 DEC 2014.
13.2.1 Overview of changes
Amendment 4 was initiated to incorporate changes to the safet y reporting procedures and 
change of Sponsor responsibilities following the acquisition of Conceptus, Inc. by[CONTACT_8980], LLC.  In addition, administrative changes were made, including the change of the 
Sponsor’s medical expert [INVESTIGATOR_8999]. A
few minor editorial/typographical errors were corrected for clarification.
Revision of protocol and CRFs w as needed as a result of change in sponsor from Conceptus, 
Inc. to Bay er HealthCare. 
(1) The text from Version 3 of the protocol was transferred to the Bay er protocol template, 
which resulted in:
a)shifting the sequence of sections in order to conform with the Bay er protocol template,
b) modification of section headers as the Bay er protocol template is not specific to 
medical device studies,
c)population of protocol sections that previously  did not exist in Version [ADDRESS_8247] p ractices. 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 41of 82
(2) The safet y reporting process was transferred from Conceptus to Bayer, so language in the 
protocol was modified to reflect this change.
(3) Adverse events were previously  categorized by  [CONTACT_8981] (Conceptus) 
in terms of rel atedness and severit y to the Essure device; the current Sponsor (Bay er) will 
only categorize SAEs/SADEs in terms of expectedness, seriousness, and causal relationship 
to the Essure device which is Bay er’s usual practice. Investigator responsibilities for 
categorizing AEs are unchanged. 
(4) The exclusion criteria were modified so that potential subjects with I UD/I US in place 
would be excluded only  if they  were unwilling to have the IUD/IUS removed prior to 
Nova Sure EA. Also, subjects are permitted to have endometrial sampling (to ensure benign 
causes for menorrhagia) or IUD/IUS removal prior to the time of Nova Sure EA.
(5) Appendix E was added to show general stud y timelines.
(6) Minor edits to clarify  language from the previous protocol version.
13.2.2 Changes to the protocol text
In this section, all affected protocol sections are detailed; the sequence of the sections follows the 
structure of the original protocol.  In the display of modifications, the “old text” refers to the 
protocol version preceding this ame ndment.  Deletions are crossed out in the “old text”.  
Additions are underlined in the “new text”.  Corrections of typi[INVESTIGATOR_8940]. Specific changes to the text are described by [CONTACT_8982].
Title page and synopsis
The title page in the Bayer template was added and the sponsor’s medically  responsible part y 
was added.   A synopsis section was added to summarize the main points of the protocol.
1. Introduction
The majority  of the content of the introduction is unchanged.  It was transferred to the new 
protocol template.   The specific text changes areshown below.
1.2. Risk of Pregnancy
Old text :
Although women undergoing EA must be finished with childbearing, EA should not be 
considered a means of steriliza tion.  Pregnancy  should not be elected after an ablation because 
it can be dangerous for both the fetus and mother; therefore, women need to have a reliable contraceptive method if they  choose to undergo EA.  The Essure procedure is a hy steroscopic 
permane nt sterilization method and a complement to various EA technologies.  Contrariwise, 
women who have undergone hy steroscopic sterilization with the Essure procedure may  
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 42of 82
become candidates for EA procedures in the future should they  develop menorrhagia 
requiri ng treatment.
New text :
Although women undergoing EA must be finished with childbearing, EA should not be 
considered a means of sterilization.  Pregnancy  should not be elected after an ablation because 
it can be dangerous for both the fetus and mother; the refore, women need to have a reliable 
contraceptive method if they  choose to undergo EA.  The Essure procedure is a hy steroscopic 
permanent sterilization method and a complement to various EA technologies.  Women who 
have undergone h ysteroscopic sterilization with the Essure procedure may  become candidates 
for EA procedures should they develop menorrhagia requiring treatment in the future .  This 
study  evaluates how the NovaSure EA may  affect the effectiveness and safety  of Essure .
1.5.3 Risk Analysis and Co nclusions from Prior Reported Data
Old text :
Clinical and commercial studies have evaluated over [ADDRESS_8248] of this protocol will evaluate the 
ability  of Essure micro- inserts to maintain contraception following NovaSure EA, providing 
further data to assess the risk-benefit ratio.
New text :
Clinical and commercial studies have evaluated over [ADDRESS_8249] frequent adverse event that could be attributed to performing the two technologies together was the possibility of displacing or dislodging an implanted Essure micro -insert 
when performing NovaSure EA.  The larger studies demonstrated that the Essure micro -
inserts did not alter performance of NovaSure EA.  The benefit of performing NovaSure EA in patients wearing the Essure micro -inserts outweighs the risk of the adverse events that ar e 
expected to occur.  This clinical study  will evaluate the ability  of Essure micro- inserts to 
maintain contraception following NovaSure EA, providing further data to assess the risk -
benefit ratio.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 43of 82
1.6. Regulatory and Commercial Labelling History
New text:
Further details can be found in the IFU, which contains comprehensive information on the 
study  device.
2. Objectives
The objectives were not changed but they  appear ina different location in the format of this 
amended protocol.
3. Investigators and other study personnel
The content of this section is primarily  from the Bay er template but also has language taken 
verbatim from the previous version of the protocol.4. Study design
Old text:
Design overview
This PAS is a prospective, multi -center, single -arm observational study  to monitor and 
evaluate the effectiveness and safet y of Essure when NovaSure is performed following a 
successful Essure Confirmation Test.  The PAS will be conducted at up to [ADDRESS_8250] will be considered. 
New text:
Design overview
This PAS is a prospective, multi -center, single -arm observational study  to monitor and 
evaluate the effectiveness and safet y of Essure when NovaSure is performed following a 
successful Essure Confirmation Test.  The PAS will be conducted at up to [ADDRESS_8251] will be considered. 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 44of 82
5. Study population (section title was Recruitment Strategy in prior version)
5.1.1 Inclusion criteria
Old text :
6.Subject is willing to accept the risk of pregnancy  while relying on the Essure micro-
inserts for prevention of pregnancy
New text :
6.Subject is willing to accept the risk of pregnancy  while rel ying on the Essure micro-
inserts for prevention of pregnancy  following a NovaSure ablation procedure for 
menorrhagia
5.1.2. Exclusion criteria
Old text:
5.Subject is currentl y wearing an intrauterine device 
6.Subject has undergone any  other intrauterine procedures in between Essure 
placement procedure and NovaSure EA.
7.Subject is scheduled to undergo an y other intrauterine p rocedures at the time of 
NovaSure EA.
New text:
5.Subject is currentl y wearing an intrauterine device or intrauterine s ystem and is 
unwilling to have it removed before the NovaSure EA procedure
6.Subject has undergone any  other intrauterine procedures (except endometrial biopsy  
or sampling, if required or indicated ; IUD/IUS removal is permitted) in between 
Essure placement procedure and NovaSure EA.
7.Subject is scheduled to undergo an y other intrauterine procedures at the time of 
NovaSure EA (except endometrial biopsy or sampling , if required or indicated; 
IUD/IUS removal is permitted ).
5.2 Withdrawal of subjects from study
5.2.1 Withdrawal
New text :
Subjects must be withdrawn from the stud y for the following reasons:
At their own request or at the request of their legally  acceptable representative
At any  time during the study  and without giving reasons, a subject may  decline to 
participate further.  The subject will not suffer an y disadvantage as a result.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 45of 82
If, in the investigator's opi[INVESTIGATOR_1649], continuation of the study  would be harmful to the 
subject's well -being
Subjects may  be withdrawn from the study  for the following reasons:
At the specific request of the sponsor and in liaison with the investigator (e.g. obvious 
non-compliance, safet y concerns).
Subjects may be terminated from the study  by [CONTACT_737].  Reasons for termination of a 
subject from the stud y may include, but are not limited to, the following:
Subject does not retain device (e.g. due to removal of device, expulsion, 
salpi[INVESTIGATOR_8926] -tubal surgeries)
Death
An AE preventing stud y participation
Lost to follow -up and inability  to contact [CONTACT_423].  Note that if a subject who is lost 
to follow -up is recontact[INVESTIGATOR_530], the subject will not be considered to have withdrawn from 
the study .
A subject who discontinues study  participation prematurely  for any  reason is defined as a 
“dropout” if the subject has alread y undergone the NovaSure procedure .
A subject who, for an y reason (e.g . failure to satisfy  the selection criteria), terminates the 
study  before the time point used for the definition of “dropout” (see above) is regarded a 
“screening failure”.
Any subject removed from the trial will remain under medical supervision until disc harge or 
transfer is medically  acceptable.
In all cases, the reason for withdrawal must be recorded in the case report form (CRF) and in 
the subject's medical records.
Details for the premature termination of the study  as a whole (or components thereof [e. g. 
centers, treatment arms, dose steps]) are provided in Section 10 (Premature termination of the 
study ).
5.2.[ADDRESS_8252] signed the informed consent form (I CF), they  will be identified by  a 
unique 5-digit subject identification number.  The subject identification number which will 
identify  the subject throughout the study  is constructed as follows:
Digit 1- 2:  Study  center number
Digit 3-5: Subject number, unique within any  study  center.  Sequential number 
reflecting the order in which the subjects signed the I CF at the center.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 46of [ADDRESS_8253] in the previous version by [CONTACT_8983] t he previous version of the protocol.
6. Treatment
6.1 Treatments to be administered
In this stud y, the NovaSure EA procedure following successful placement of a commercially 
available Essure device is the treatment being administered.  The Essure device , with the 
exception of relatedness of AEs, and placement procedure are not being evaluated.
6.2 Identity of study treatment
Not applicable.
6.3 Treatment assignment
This is a non- randomized, continuous enrollment study in which all eligible subjects will be 
asked to enroll.  To avoid selection bias, Investigators will offer enrollment in the study  to all 
eligible subjects consecutively  (as they  present themselves to the I nvestigator).
A subject may  not be enrolled in the study  until she has an Essure confirmation test done that 
documents bilateral satisfactory  device location and fallopi[INVESTIGATOR_8941].  If subject has 
had Essure placement but she does not have an Essure Confirmation Test that documents 
bilateral satisfactory  device location and fallopi[INVESTIGATOR_8941], she may  repeat the Essure 
Confirmation Test.
6.4 Dosage and administration
Not applicable.
6.5 Blinding
Blinding will not occur in this study.  Procedures and Follow- up for emergency  unblinding 
are not required.
6.6 Device logistics and accountability
Not applicable.
6.7 Treatment compliance
The Essure device is intended for subjects who desire permanent contraception (female 
sterilization) and is not intended to be removed.
6.[ADDRESS_8254]'s well- being will be 
allowed during the stud y.  Any  medical treatment administered for the treatment of AEs that 
occur during the stud y will be recorded in the CRF.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 47of 82
[IP_ADDRESS]. NovaSure EA Procedure (Day 0)
Old text:
The Investigator or designated study  staff will confirm that the subject has not experienced an 
adverse event since the Eligibility and Screening Visit.  
The NovaSure procedure will be performed in accordance with t he NovaSure EA IFU and 
Controller Operator’s Manual.  At the time of the procedure, subject’s uterine cavity  will be assessed to ensure that uterine 
cavity  length is not less than 4 cm and uterine cavity  width is not less than 2.5 cm; if they  are, 
subject is ineligible to participate in the study .  
New text:
The Investigator or designated study  staff will confirm that the subject has not experienced an 
adverse event since the Eligibility and Screening Visit.  The NovaSure procedure will be performed in accordance with the NovaSure EA IFU and 
Controller Operator’s Manual.  
At the time of the procedure, subject’s uterine cavity  will be assessed to ensure that uterine 
cavity  length is not less than 4 cm and uterine cavity  width is not less than 2.5 cm (see 
Exclusion criteria 8; Section 5.1.2); if they  are, subject is ineligible to participate in the study .   
[IP_ADDRESS] Notification of Other Relevant EventsOld text:
The subject should be instructed at the beginning of the study  to inform the site immediately  
if subject has had or is scheduled to have an y surgery  which may  remove some or all of her 
reproductive organs (i.e. hy sterectom y, salpi[INVESTIGATOR_8931] y).  The site should call 
Conceptus immediately  to make arrangements to have extirpated tubes con taining the micro -
inserts shipped to Conceptus which will in turn, send them out for histological evaluation .
The subject will also be instructed to contact [CONTACT_8968] y if, at an y time 
during the stud y, subject thinks she might be pregnant .
If a subject experiences a micro-insert expulsion or removal during or following the NovaSure 
procedure, subject will be followed for the duration of the adverse event, then terminated from the study .
New text:
The subject should be instructed at the beginning of the study  to inform the site immediately  
if subject has had or is scheduled to have an y surgery  which may  remove some or all of her 
reproductive organs (i.e. hy sterectom y, salpi[INVESTIGATOR_8931] y).  
The subject will also be instructed to contact [CONTACT_8968] y if, at an y time 
during the stud y, subject thinks she might be pregnant. 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 48of [ADDRESS_8255] in the previous version by [CONTACT_8984].
7.2 Population characteristics 
7.2.1 Demographics
Demographic data collected include, but may  not be limited to, date of birth (as allowed b y 
local law), race, and ethnicity .
7.2.2 Medical history
Medical history  findings (i.e. previous diagnoses, diseases or surgeries) meeting all criteria 
listed below will be collected:
Not pertaining to the study indication
Start before signing of the informed consent 
Considered relevant to the study .
Detailed instructions on the differentiation between (i) medical history  and (ii) adverse events 
can be found in Section [IP_ADDRESS].
Section 7.[ADDRESS_8256] in the previous version b y name [CONTACT_9004].
7.4. Safety
Old text:
J. Safety
J.[ADDRESS_8257] signs the 
informed consent through the time the patient terminates from or completes the study .  
Subjects who experience an adverse event will be followed until the resolution of the adverse 
event or sta bilization of the patients health (in the case of long -term event), regardless of a 
scheduled or unscheduled termination.  An event will be considered resolved when the subject 
health returns to its baseline state.  
J.1.2 Adverse events will be recorded on the CRFs b y the Investigator or stud y staff.  Event, 
date of onset, severit y, duration, and relationship to device or procedure will be recorded on 
the appropriate CRF.  
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 49of 82
Investigator must determine whether adverse event meets the definition of a serious 
adverse event; if so, it must be reported as required by  [CONTACT_8985] J.3.
Investigator must determine whether adverse event is an unanticipated adverse device 
effect; if so, it must be reported as required b y Section J.4.
J.1.[ADDRESS_8258] clinical signs (including abnormal laboratory  findings) in subjects, users 
or other persons, whether or not related to the investigational medical device and including 
events related to the procedure(s) involved.
Relate dness
Not Related –The adverse event is clearl y not related to the intervention
Possible – The adverse event may  be related to the intervention
Probable – The adverse event is likely  related to the intervention
Definite – The adverse event is clearl y related to the intervention
Serious adverse event is an event that:
Led to death,
Led to serious deterioration in the health of the subject, that either resulted in
oA life -threatening illness or injury , or
oA permanent impairment of a bod y structure or a b ody function, or
oIn-patient or prolonged hospi[INVESTIGATOR_059], or
oMedical or surgical intervention to prevent life- threatening illness or injury  or 
permanent impairment to a body  structure or a body  function, or
Led to fetal distress, fetal death or a congenita l abnormality  or birth defect
Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure required by [CONTACT_8986], without serious deterioration in health, is not considered a serious adverse event.
Severity
Mild -asymptomatic or mild symptoms; clinical or diagnostic observations only ; intervention 
not indicated.Moderate - minimal, local, or noninvasive intervention indicated; limiting age- appropriate 
instrumental activities of daily  living (ADL).
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 50of 82
Severe or medicall y significant but not immediately  life-threatening -hospi[INVESTIGATOR_8942]; disabling; limiting self -care ADL.
Life-threatening consequences -urgent intervention indicated.
Death related to AE.
Unanticipated adverse device effect mea ns an y serious adverse effect on health or safet y or 
any life-threatening problem or death caused by , or associated with, a device, if that effect, 
problem, or death was not previously  identified in nature, severity , or degree of incidence in 
the investiga tional plan or application (including supplementary  plan or application), or any  
other unanticipated serious problem associated with a device that relates to the rights, safet y, 
or welfare of subjects.
J.3 Serious Adverse Events Reporting Requirements
J.3.1 If the adverse event is a serious adverse event (including device or procedure -related 
adverse events/effects and deaths), the Investigator must report it immediately  (within 24 
hours) b y telephone to Conceptus at [PHONE_179].  The Investigator will sen d to Conceptus 
all pertinent paperwork (discharge summaries, office notes, etc.) within [ADDRESS_8259]’s subsequent medical course must be submitted to Conceptus 
until the event has subsided or, in case of permanent impair ment, until the event stabilizes and 
the overall clinical outcome has been ascertained.
The Investigator must also report all required adverse events to the relevant IRB / Ethics 
Committee in accordance with I RB / Ethics Committee requirements.  
J.[ADDRESS_8260] report it to Conceptus within 3 working day s after the 
Investigator becomes aware of the event.  
The Investigator will send to Conceptus all pertinent paperwork (discharge 
summaries, office notes, etc.) within 5 working day s.  
Reports relating to the subject’s subsequent medical course must be submitted to 
Conceptus until the event has subsided or, i n case of permanent impairment, until the 
event stabilizes and the overall clinical outcome has been ascertained.
The Investigator must report it to the Ethics Committee / I RB within the required time 
frame.
J.[ADDRESS_8261] to Medical Device Reporting (MDR) 
regulations.  Conceptus’ product surveillance department will review all serious adverse 
events and unanticipated adverse device effects and determine their reportability  to FDA 
according to 2 1 Code of Federal Regulations 803 "Medical Device Reporting."   Reporting 
MDRs to FDA is required when the manufacturer (Conceptus, Inc.) becomes aware of 
information that reasonably  suggests that a marketed device has or may  have caused or 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 51of [ADDRESS_8262] contributed to a death or serious injury , Conceptus’ product surveillance department 
will notify  the complaint handling function of the manufacturer of the device (Hologic, Inc.).
J.6 Device Failures and Malfunctions
All device failures and malfunctions should be reported to Conceptus on the appropriate CRF.  
These will be reported in the PAS results.  Essure Sy stem devices that fail or malfunction 
should be returned to Conceptus for anal ysis after appropriate decontamination per Study  Site 
guidelines.  
J.6.1 Device Failure
For this protocol, device failure will be defined as the failure of a device to perform as 
intended even though the device was succes sfully  used according to the labeling. (E.g. 
pregnancy  when micro -insert properl y located and fallopi[INVESTIGATOR_8935]; continued 
menorrhagia despi[INVESTIGATOR_040] a completed endometrial ablation procedure)
J.6.2 Device Malfunction
For this protocol, a device malfunction will be defined as the failure of a device to meet its 
performance specifications or to function as intended when used according to the labeling.  
(E.g. Difficulties with deploy ment or detachment of micro -insert; device difficulties when 
conducting endometrial ablation)
Contact [CONTACT_8987], contact [CONTACT_8988]’ Product Surveillance department at 
 option 5.
New text:
[IP_ADDRESS]. Definitions
[IP_ADDRESS].[ADDRESS_8263] medical occurrence (i.e. any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study .  Therefore, an AE may  or may  not be temporally  or causally  associated with the use of 
a medicinal (investigational) product or device.
[IP_ADDRESS].1.[ADDRESS_8264] (ADE)
An AE related to the use of Essure, including AEs resulting from insufficient or inadequate 
instructions for use, deploy ment, implant (placement), installation or operation or any  
malfunction of the investigational medical device, use error or from intentional misuse of the 
medical device.
[COMPANY_003]
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 52of 82
[IP_ADDRESS].1.[ADDRESS_8265] (UADE)
An AE is considered unanticipated if, by  [CONTACT_5942], incidence, severity , or outcome it has not 
been identified in the IFU.
(Added as  footnote 24): The definition of UADE used in protocol version 3.0 (Conceptus) is
consistent with the definition of [LOCATION_003]DE in this protocol version (4.0).   The definition of 
UADE in this protocol version (4.0) onl y applies to non- serious events.
[IP_ADDRESS].2 Serious adverse event (SAE)
An SAE is classified as any untoward medical occurrenc e but is not related to a medical device 
that, meets any  of the following criteria:
1.Led to death
2.Led to a serious deterioration in the health of the subject that:
oresulted in a life -threatening illness or injury
oresulted in a permanent impairment of a bod ystructure or bod y function
orequired hospi[INVESTIGATOR_8943] a medical or surgical intervention to prevent permanent impairment 
to body  structure or function
Note :  For the purposes of this protocol, ectopic pregnancy  and spontaneous abortion are 
alway s considered as important events and therefore reported as SAEs.
[IP_ADDRESS].2.1 Incident
Any malfunction or deterioration in the characteristics and / or performance of a device, as 
well as an y inadequacy in the lab eling or the instructions for use which, directly or indirectl y, 
led to, might lead to or might have led to the death of a patient, or user or of other persons or 
to a serious deterioration in their state of health.
Any event which meets all three basic re porting criteria (A -C) is considered an Incident:
B.An event has occurred, e.g.
• malfunction or deterioration in the characteristics or performance
• unanticipated adverse reaction or unanticipated side effect
• interactions with other substances or products
• degradation / destruction of the device
• inappropriate therap y
• inaccuracy  in the labeling, instructions for use including omissions or 
deficiencies
B) The device is suspected to be a contributory  cause of the incident.
C) The event led, or might have led, to one of the following outcomes:
•death of a patient, or user, or other person
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 53of 82
•serious deterioration in state of health of a patient, user or other person
(See European Commission, Medical Devices: Guidance document MEDDEV 2.12 -1)
[IP_ADDRESS].2.[ADDRESS_8266] ([LOCATION_003]DE)
An unanticipated serious adverse device effect (U SADE) is an y serious adverse effect on 
health or safety  or any  life-threatening problem or death caused by , or associated with, a 
device, if that effect, problem, or death was not previously  identified in nature, severity , or 
degree of incidence in the investigational plan or application (including supplementary  plan or 
application), or an y other unanticipated serious problem associated with a device that relat es 
to the rights, safet y, or welfare of subjects.
[IP_ADDRESS].3 Medical Device Report (MDR) Reportable Event
(1) An event that user facilities become aware of that reasonabl y suggests that a device 
has or may  have caused or contributed to a death or serious i njury ; or
(2) An event that manufacturers or importers become aware of that reasonabl y suggest 
that one of their marketed devices:
(i) May have caused or contributed to a death or serious injury , or
(ii) Has malfunctioned and that the device or a similar d evice marketed b y the 
manufacturer or importer would be likely  to cause or contribute to a death or 
serious injury  if the malfunction were to recur.
(See 21 CFR 803 Medical Device reporting)
An MDR corresponds to the definition of Incident.
[IP_ADDRESS].4 D evice deficiency
Inadequacy  of Essure related to its identity , quality , durability , reliability , safet y or 
performance, such as malfunction, misuse or use error and inadequate labeling.
[IP_ADDRESS].4.1 Device failure
Failure of Essure to perform or function as intended, including an y deviations from the 
performance specifications or intended use (e.g., pregnancy  when micro -insert properl y 
located and fallopi[INVESTIGATOR_8935]; continued menorrhagia despi[INVESTIGATOR_040] a completed endometrial 
ablation procedure) .For the purposes of this study, a pregnancy that occurs in a subject told 
to rely  on a commercially  available Essure device for contraception is a device failure.
[IP_ADDRESS].4.2 Device malfunction
Failure of Essure to meet its performance specifications or otherwise perform as intended 
when used in accordance with the IFU (e.g., difficulties with deployment or detachment of 
micro-insert; device difficulties when conducting endometrial ablation).
[IP_ADDRESS].[ADDRESS_8267]
The Important Medical Events (IME) list is developed and published by  [CONTACT_8969]  (EMA) (http://eudravigilance.ema.europa.eu/human/textforI ME.asp).  All 
AEs reported in this study will be reviewed against the most current IME list periodically , and 
any events that are contained on the IME list will be specifically  reviewed and the 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 54of 82
Investigator will be asked to review and confirm whether or not the event meets the criteria 
for seriousness in his/her opi[INVESTIGATOR_1649].  I n addition, the following events of special interest will be 
closely  reviewed by  [CONTACT_456]’s study  medical expert:
Upper genital tract infections (for example: endometritis, salpi[INVESTIGATOR_8936] -oophoritis, 
salpi[INVESTIGATOR_8937]).
Expulsion or migration of Essure inserts.
[IP_ADDRESS]. Classifications for adve rse event assessment
All AEs will be assessed and documented b y the investigator according to the categories 
detailed below. 
[IP_ADDRESS].1. Seriousness
For each AE, the seriousness must be determined according to the criteria given in 
Section [IP_ADDRESS].
[IP_ADDRESS].2. Severity
The severit y of an AE is classified according to the following categories:54
[IP_ADDRESS].3 Causal relationship 
The assessment of the causal relationship between an AE and the administration of treatment 
isthe investigator’s responsibility , and is a clinical decision based on all available information 
at the time of the completion of the CRF.  The assessment is based on the question of whether 
there was a “reasonable causal relationship” to the study  treatm ent in question.
The following information must be entered on the CRF for all AEs and SAEs:
Relation to the Essure device
Relation to the NovaSure device
Relation to the NovaSure procedure
Relation to a pre -existing condition (additional description requir ed)
Possible choices for causality  include:
Not related
Unlikely  to be related
Possibly  related
Probably  related
Definitely  related
Important factors to be considered in assessing the relationship of the AE to the device or 
procedure include:
                                                
54(existing definitions of severity were maintained in this section, only the introductory sentence is new)
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 55of 82
- The temporal sequence from the Essure placement procedure:  The event should occur 
after the procedure.  
-Underl ying, concomitant, intercurrent diseases:  
Each event should be evaluated in the context of the natural history  and course of the 
Essure procedure and any  other medical conditions the subject may  have.
-Concomitant medication or procedures: 
Any drugs the subject is taking or additional procedures the subject receives should be 
examined to determine whether an y of them may  be suspected to cause th e event in 
question.
[IP_ADDRESS].4. Outcome
The outcome of the AE is to be documented as follows: 
Recovered without treatment
Recovered with treatment
Not recovered with permanent impairment
Death
Undetermined, describe:
[IP_ADDRESS]. Assessments and documentation of adverse events
Investigators must collect all AEs for each subject from the time of signing of the informed 
consent through the end of subject study participation, whether or not deemed related to the 
investigational device or procedure.  All AE data will be recorded on the CRFs as well as 
documented in the subject’s medical record.
All SAEs and SADEs will be followed until the event has subsided or, in case of permanent 
impairment, until the event stabilizes and the overall clinical outcome has been as certained.  
Investigator must determine whether adverse event meets the definition of a serious adverse 
event; if so, it must be reported as required b y Section [IP_ADDRESS].
Any SAE or incident will be reviewed and pr ocessed by  [CONTACT_8971].  
Investigators must document all device failures, malfunctions and use errors, including the 
assessment of whether the event is considered an incident (ADE) using the Device 
Malfunction and F ailure CRF.
Investigator must determine whether adverse event is an unanticipated adverse device effect; 
if so, it must be reported as required b y Section [IP_ADDRESS].
Because an approved device will be used for the pl acement procedure, an y device 
malfunctions will be reported to the sponsor’s Product Surveillance department.  Device 
malfunctions will not be anal yzed as part of this study  as the placement procedure and device 
are not being evaluated.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 56of 82
[IP_ADDRESS]. Reporting of serious adverse events
The definition of serious adverse events (SAEs) is given in Section [IP_ADDRESS].  These include 
device deficiencies that may have led to a SAE if a) suitable action had not been taken or b) 
intervention had not been made or c) if circumstances had been less fortunate.  These are 
handled under the sponsor’s SAE reporting s ystem.
Investigator’s notification of the sponsor
All investigators will be thoroughl y instructed and trained on all relevant aspects of the 
investigator’s reporting obligations for SAEs.  This information, including all relevant contact 
[CONTACT_8972], is summarized in the investigator site file.  This information will be updated as 
needed.
All SAEs and incidents (ADEs) occurring during the observation period defined in 
Section [IP_ADDRESS] must immediately  (within 24 hours of the investigator’s awareness) be 
reported to the sponsor.  An SAE form must also be completed within 24 hours of the 
investigator awareness and forwarded to the sponsor’s designated recipi[INVESTIGATOR_841].  
Each SAE and incident must be followed up until resolution or stabilization by  [CONTACT_8989][INVESTIGATOR_841].  An y SAE or incident occurring after the pr otocol -
defined observation period will be processed by [CONTACT_8974].
In addition, device failures, malfunctions or incidents must be reported to Sponsor within 24 
hours via fax or email.  
Ectopic pregnancies and spon taneous abortions will always be considered as SAEs and 
reported as such to the Sponsor
Notification of the independent ethics committee (IEC)s / institutional review board 
(IRB)s
Notification of the IECs / I RBs about all relevant events (e.g. SAEs, incidents, UADEs, 
device failures, device malfunctions) will be performed by [CONTACT_8975].
Notification of the authorities
The processing and reporting of all relevant events (e.g. SAEs, incidents, UADEs, device 
failures, device malfunctions) to the authorities will be done b y the sponsor according to all 
applicable regulations.
Because this is a PAS, the Essure S ystem is subject to Medical Device Reporting (MDR) 
regulations.  The sponsor will review all serious adverse events and unanticipated adverse 
device effects and determine their reportabilit y to FDA according to 21 Code of Federal 
Regulations 803 " Medical Device Reporting "   Reporting MDRs to FDA is required when the 
sponsor becomes aware of information tha t reasonably  suggests that a marketed device has or 
may have caused or contributed to a death, serious injury  or long -term pain necessitating 
surgical intervention, or has malfunctioned, and that the device or a similar device marketed 
by [CONTACT_8976] a death or serious injury  if the 
malfunction were to recur.  In the event information is received that the NovaSure Sy stem 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 57of [ADDRESS_8268] contributed to a death or serious injury , the sponsor will notify  
the complaint handling function of the manufacturer of the device (Hologic, Inc.).
Sponsor’s notification of the investigational site
The sponsor will inform all investigational sites about reported relevant events (e.g. SAEs 
incidents, UADEs, device failu res, device malfunctions) according to all applicable 
regulations.
If the adverse event is also an unanticipated adverse device effect, the investigator must report 
it to the sponsor within 3 working days after the investigator becomes aware of the event. 
The investigator will send to the sponsor all pertinent paperwork (discharge summaries, office 
notes, etc.) within [ADDRESS_8269]’s subsequent medical course must be submitted to the sponsor 
until the event has subsided or, in case of permanent impairment, until the event stabilizes and 
the overall clinical outcome has been ascertained.  The investigator must report it to the Ethics 
Committee / I RB within the required time frame.
[IP_ADDRESS]. Expected adverse events
For this medical device study , the applicable reference document is the most current version 
of the IFU.
The expectedness of AEs will be determined b y the sponsor according to the applicable 
reference document and according to all local regulations.
7.4.[ADDRESS_8270] in the previous version by  [CONTACT_8990].
New text:
If a subject becomes pregnant at an y time during the study, the pregnancy will be counted as 
an Essure device failure following a NovaSure ablation.  Subject will also be counseled that 
she can no longer rel y on Essure for contraception.  
Sections 7.[ADDRESS_8271] in the previous version by  [CONTACT_8991].7.5 Other procedures and variables
Not applicable.
7.6 Appropriateness of procedures / measurements
Not applicable.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 58of 82
8.1. General considerations 
Old text :
Baseline NovaSure EA and follow- up data will be summarized using the appropriate 
statistical method.  Continuous variables will be summarized using means, standard 
deviations, medians and ranges.  Categorical data will be summarized using frequency  rates 
(e.g., count/sample size).
New text:
The statistical anal ysis plan will be finalized and signe d off before data release for anal ysis. 
Baseline NovaSure EA and follow- up data will be summarized using the appropriate 
statistical method.  Continuous variables will be summarized using means, standard 
deviations, medians and ranges.  Categorical data w ill be summarized using frequency  rates 
(e.g., count/sample size).
Sections 8.[ADDRESS_8272] in the previous version by [CONTACT_8991].
8.2 Analysis sets 
Primary effectiveness cohort
All subjects who meet study  entry  criteria, sign a study -specific ICF, and undergo insertion of 
the NovaSure device transcervically .
Primary safety cohort
All subjects in whom a NovaSure procedure is attempted.
8.3 Variables
Primary :  Occurrence of confirmed pre gnancy  at [ADDRESS_8273].
Secondary : Adverse event data
8.4.1 Primary variable
Old text:
For example, if there are 0 failures in 200 × 12 = 2,400 women-months, the posterior 
distribution of the monthly  failure rate is beta (0.5, 0.5 + 2400).  The upper Bay esian credible 
interval is (in Excel) betainv (.975, 0.5, 0.5 + 2400) = 0.[ZIP_CODE].  The upper 95% credi ble 
interval for the 1 -year rate is 1- (1-0.[ZIP_CODE])12= 0.012 or 1.2%.  This value meets the pre -
determined stud y success threshold of 2.1%.  
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 59of 82
New text:
For example, if there are 0 failures in 200 × 12 = 2,400 women-months, the posterior 
distribution of the monthly  failure rate is beta(0.5, 0.5 + 2400).  The upper Bay esian credible 
interval is (in Excel) betainv (.975, 0.5, 0.5 + 2400) = 0.[ZIP_CODE].  The upper 95% credible interval for the 1 -year rate is 1- (1-0.[ZIP_CODE])
12= 0.0125 or 1.25%.  This value meets the p re-
determined stud y success threshold of 2.1%.  
8.5. Planned interim analyses
Old text :
Based upon Conceptus data on the average monthly  rate of Essure micro- insert placement and 
estimates of NovaSure procedures b y physicians throughout the [LOCATION_002], it is believed 
that each PAS Investigator/site will perform about 1 procedure per month.  As such, 
Conceptus expects this PAS to maintain the following timeline:
Expected date of stud y initiation October [ADDRESS_8274] follow-up April 2017
Expected date complete final PAS report June 2017
New text and new Table :
For the first two y ears of the PAS, an interim PAS status report will be submitted every  6 
months from the date of the pre -market approval (PMA) letter or other negotiated starting
date (i.e., PAS initiation).  Ongoing interim PAS status reports will be submitted annually , 
thereafter, until the final PAS report is written after the termination or completion of the PAS.  
The ongoing interim reports and final PAS report will include i nformation related to PAS 
methodology  and results/endpoints.
(The table was moved to Section 14 (Appendices –Appendix E) with changes in wording and 
dates.)
9. Data management and quality assurance
Old text:
J.9A.[ADDRESS_8275] the PAS properl y.  A site qualification / 
site initiation visit will be conducted with each study  site in order to orient the prospective 
Investigator and stud y staff to the PAS and protocol, applicable regulations and requirements, 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 60of [ADDRESS_8276] keepi[INVESTIGATOR_007], etc.  
PAS site monitoring will be perfo rmed b y Conceptus personnel or their designees.  Each site 
will be routinely  remotely /centrall y/on-site monitored to ensure that the PAS is conducted in 
full compliance with all applicable regulations, and with the PAS protocol.  Any  evident 
pattern of non-compliance with respect to these standards will be cause for the site to be put 
on probation for a specified period.  If corrective actions are not subsequently  undertaken, the 
PAS site will be asked to withdraw.
A designated site monitor will maintain pe rsonal contact [CONTACT_8992] b y phone, mail, and on- site visits.  The site monitor will compi[INVESTIGATOR_8944].  Monitoring will ensure continued PAS protocol 
compliance, adequate patient enrollment and accurate data reporting.
At the close of the PAS, the site monitor will perform a final on -site close- out visit.  The 
purpose of this visit is to collect all outstanding PAS data documents, ensure that the 
Investigator's files are accurate an d complete, ensure completion and submission of I RB / 
Ethics Committee final report, review record retention requirements with the Investigator, and 
ensure that all applicable requirements are met for the PAS.  The observations and actions 
made at this visit will be documented as a final report.  One year following the close -out visit, 
the Investigator must provide a financial disclosure form to Conceptus.
New text:
9.[ADDRESS_8277] will be used at the site to identify the source data for 
all data points collected and the monitor will work with the site to complete this.
Data recorded from “only screened subjects (screening failures)”
Data of 'onl y screened subjects' will be recorded at least as source data, as far as the reason for 
the premature discontinuation is identifiable.  At minimum, data to be recorded in the CRF 
are demographic information (subject number, date of birth/age, sex, race and ethnicity ), the 
reason for premature discontinuation and date of last visit.  These data will be transferred to 
the respective database.
For screening failure s with an SAE, the following additional data should be collected in the 
CRF, in addition to demographic information, primary  reason for discontinuation and date of 
last visit:
All information about the SAE
All information related to the SAE such as: 
oConcomitant medication
oMedical history
oOther information needed for SAE complementary  page
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 61of 82
9.2 Monitoring
In accordance with applicable regulations, GCP, and sponsor’s procedures, monitors will 
contact [CONTACT_8977] y to review with the site staff the protocol, study  
requirements, and their responsibilities to satisfy  regulatory , ethical, and sponsor’s 
requirements.  When reviewing data collection procedures, the discussion will also include 
identification and documentation of source dat a items.
The sponsor/designee will monitor the site activity  to verify  that the:
Data are authentic, accurate and complete
Safety  and rights of subjects are being protected
Study  is conducted in accordance with the currently  approved protocol (including 
study treatment being used in accordance with the protocol)
Any other study  agreements, GCP, and all applicable regulatory requirements are met.
The investigator and the head of the medical institution (where applicable) agrees to allow the 
monitor direct ac cess to all relevant documents.
9.3 Data processing
The data collection tool for this study  will be via electronic CRF (eCRF).  Subject data 
necessary  for anal ysis and reporting will be entered/transmitted into a validated database or 
data sy stem.  Clinica l data management will be performed in accordance with applicable 
sponsor’s standards and data cleaning procedures.  This is applicable for data recorded on 
CRF as well as for data from other sources.
For data coding (e.g. AEs), internationally  recognized and accepted dictionaries will be used.
9.4 Audit and inspection
To ensure compliance with GCP and regulatory  requirements, a member of the sponsor’s 
quality  assurance unit may  arrange to conduct an audit to assess the performance of the study  
at the study site and of the study  documents originating there.  The investigator/institution 
will be informed of the audit outcome.
In addition, inspections by [CONTACT_8993](s)/I RB(s) are 
possible.  The investigator should notify the sponsor immediately  of any  such inspection.
The investigator/institution agrees to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the time of his/her staff to the auditor/inspector to 
discuss findi ngs and an y issues.  Audits and inspections may  occur at any  time during or after 
completion of the study .
9.[ADDRESS_8278] that ensures that they  
are readil y available upon authorities’ request.
Subject (hospi[INVESTIGATOR_307]) files will be archived according to local regulations and in accordance with 
the maximum period of time permitted by [CONTACT_5035][INVESTIGATOR_307], institution or private practice.  Where 
the archiving procedures do not meet the minimum timelines required b y the sponsor, 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 62of [ADDRESS_8279] be made to ensure the availability  of the source documents for 
the required period.
The investigator/institution notifies the sponsor if the archival arrangements change (e.g. 
relocation or transfer of ownership).
The investigator site file is not to be destroyed without the sponsor’s approval.
The contract with the investigator/institution will contain all regulations relevant for the stud y 
center.
Section [ADDRESS_8280] in the previous version b y name [CONTACT_9004].
New text:
10. Premature termination of the study
The sponsor has the right to close this study  (or, if applicable, individual segments thereof 
[e.g. treatment arms; dose steps; centers]) at an y time, wh ich may  be due but not limited to the 
following reasons: 
If risk -benefit ratio becomes unacceptable owing to, for example,
-Safety  findings from this study  (e.g. SAEs)
-Results of any  interim analy sis
- Results of parallel clinical studies
If the stud y conduc t (e.g. recruitment rate; drop-out rate; data qualit y; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable time 
frame.
The investigator has the right to close his/her center at an y time.
For an y of the above closures, the following applies:
Closures should occur only  after consultation between involved parties.  Final decision 
on the closure must be in writing.
All affected institutions (e.g. IEC(s)/IRB(s); competent authority(ies); study center; 
head of stud y center) must be informed as applicable according to local law.
All study  materials (except documentation that has to remain stored at site) must be 
returned to the sponsor.  The investigator will retain all other documents until 
notification given b y the sponsor f or destruction.
In case of a partial study  closure, ongoing subjects, including those in post study  
follow -up, must be taken care of in an ethical manner.
Details for individual subject's withdrawal can be found in Section 5.2.1.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 63of [ADDRESS_8281] in the previous version b y name [CONTACT_9004].
New text:
11. Ethical and legal aspects
11.[ADDRESS_8282] (IRB) or Ethics Committee (EC) before study  commencement.  
Additionally , all sites will be monitored in accordance with Good Clinical Practices (GCP), 
US medical device regulations, the I nformed Consent prov isions of the Declaration of 
Helsinki, and I SO [ZIP_CODE]: Clinical investigation of medical devices for human subjects –
Good clinical practice.  The study  will be registered in accordance with worldwide regulatory  
requirements.
11.[ADDRESS_8283]’s designate d number in the 
Study  Binder.
11.[ADDRESS_8284] between the sponsor and 
the investigator /institution.
The sponsor has made the information regarding the study  protocol publicly  available on the 
internet at www.clinicaltrials.gov.  
11.4 Compensation for health damage of subjects / insurance
The sponsor maintains clinical trial insurance cover age for this study  in accordance with the 
laws and regulations of the country  in which the study  is performed.
11.[ADDRESS_8285] will be kept confidential and, to the extent permitted by  [CONTACT_3999]/or reg ulations, will not be made publicly  available.
Subject names will not be supplied to the sponsor.  Only the subject number will be recorded 
in the CRF, and if the subject name [CONTACT_9005] (e.g. pathologist report), it 
must be obliterated before a cop y of the document is supplied to the sponsor.  Study findings 
stored on a computer will be stored in accordance with local data protection laws.  As part of 
the informed consent process, the subjects will be informed in writing that representat ives of 
the sponsor, IEC/I RB, or regulatory  authorities may  inspect their medical records to verify  the 
information collected, and that all personal information made available for inspection will be 
handled in strictest confidence and in accordance with lo cal data protection laws.
If the results of the stud y are published, the subject’s identity  will remain confidential.
The investigator will maintain a list to enable subjects to be identified.
Section 12 (Reference L ist) was added per the sponsor template requirements.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 64of 82
13.3 Amendment 5
13.3.1 Overview of changes
Amendment 5 was initiated to address recruitment challenges b y revising eligibility criteria 
(see Modifications 1 and 2 below) and increase the number of sites (see Modification 3) that 
can participate in the study .In addition, other changes were made that were deemed important 
for the conduct of the study (see Modification 4).
[IP_ADDRESS] Modification 1: revision of exclusion criterion #4
For Essure confirmation tes t, the allowed time window was extended (up to 1 week prior to 3 
months from the date of placement ).
Rationale for change : the study  team received feedback from sites that they  had potential 
subjects who had undergone Essure C onfirmation Testing at just under [ADDRESS_8286]. 
Sections affected by [CONTACT_8994]:
Section 5.1.2 Exclusion criteria
[IP_ADDRESS] Modification 2: revision of exclusion criterion #[ADDRESS_8287] visualization of the inserts (for 
example, direct hy steroscopic visualization or ultrasound guidance are permitted) while 
assessing that menorrhagia is due to benign cause.
Rationale for change : While the protocol allows for endometrial biops y or sampl ing to 
assess the endometrium prior to ablation, feedback from investigators indicated that standard 
medical practice for their site included evaluation of the uterine cavit y and endometrium with 
saline infusion sonography  or diagnostic hy steroscopy [[6]].
Sections affected by [CONTACT_8994]:
Section 5.1.2 Exclusion criteria
Section [ADDRESS_8288]
[IP_ADDRESS] Modification 3: number of sites increase
The number of sites wasincreased from 15 to 30.
Rationale for the change : An increase in the number of sites is expected to increase subject 
recruitment .
Sections affected by [CONTACT_8994] :
Section 4 Study  design
Section 14 Appendices
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 65of 82
[IP_ADDRESS] Modification 4: minor clarifications
A.“Not pertaining to the study  indication” as one of the criteria for med ical history  was 
deleted.
Rationale for the changes: 
“Not pertaining to the study  indication” was included previousl y in Protocol Amendment 4 as 
this text was part of the sponsor’s protocol template. “Not pertaining to study  indication" was 
meant to specify  the diagnosis that is being studied in the trial. For this trial, all subjects are 
required to have menorrhagia due to benign causes to enroll. Therefore, it would be redundant 
to include in the me dical history  "menorrhagia" for all study  subjects, as it's understood that 
all subjects in the trial have menorrhagia in order to participate. The diagnosis of menorrhagia due to benign causes is covered b y the inclusion criteria.
Since the submission of Protocol Amendment 4, feedback has been received by  [CONTACT_8995] “not pertaining to the stud y indication” was confusing and seemed 
contradictory  with “considered relevant to the study ” Therefore, for this protocol amendment, 
“not pertaini ng to study  indication” was deleted to avoid confusion with “considered relevant 
to the study .” 
Sections affected by [CONTACT_8994] :
Section 7.2.2 Medical history
B.It was clarified that AEs should be recorded in the subjects’ source documents in 
addition to the subjects’ medical records .
Section [IP_ADDRESS] Assessments and documentation of adverse events
13.3.2 Changes to the protocol text
[IP_ADDRESS] Section 4 Study design
This section was changed as a result of Modification 3.
Old text:
The PAS will be conducted at up to 15 sites in the [LOCATION_002].
New text:
The PAS will be conducted at up to 30 sites in the [LOCATION_002].
[IP_ADDRESS] Section 5.1.2 Exclusion criteria
This section was changed as a result of Modifications 1 and 2.
Old text:
4. Subject’s Essure Confirmation Test was performed less than three months from the date of 
Essure placement
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 66of 82
New text:
4. Subject’s Essure Confirmation Test was performed less than three months (up to 1 week 
prior to 3 months is considered acceptable) from the date of Essure placement 
Old text:
6.Subject has undergone any  blind (for example without direct hy steroscopic visualization or 
ultrasound guidance) intrauterine procedures (except Endometrial biopsy  or sampling ,if 
required or indicated ;IUD/IUS removal is permitted ) in between Essure placement procedure 
and NovaSure EA 
New text:
6. Subject has undergone any  intrauterine procedure in between Essure placement procedure 
and NovaSure EA. Endometrial biopsy  or sampling if required or indicated is permitted.
IUD/IUS removal is permitted . Procedures which permit direct visualization of the inserts 
while assessing the endometrium to ensure that menorrhagia is due to benign causes (e.g. 
saline infusion sonography  or diagnostic hy steroscopy ) are permitted [6]
[IP_ADDRESS] Section 7.2.2 Medical history
This section was chang ed as a result of Modification 4 .
Deleted text:
Not per taining to the study  indication
[IP_ADDRESS] Section [IP_ADDRESS] Assessments and documentation of adverse events
This section was changed as a result of Modification 4.
Old text:
All AE data will be recorded on the CRFs as well as documented in the subject’s medical 
record.
New text:
All AE data will be recorded on the CRFs as well as documented in the subject’s medical 
record and study  source documents.
[IP_ADDRESS] Section [ADDRESS_8289]
This section was changed as a result of Modification 2.
Added text:
[6] ACOG Practice Bulletin. Clinical management guidelines for obstetrician -gynecologists. 
Number 81, May  2007. Obstet Gy necol . 2007;109(5):1233 -48.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 67of 82
[IP_ADDRESS] Section 14 Appendices
This section was changed as a result of Modification 3.
Old text/timelines:
Revised/projected stud y milestones based on enrollment rates:
Study start date –First subject enrolled  November [ADDRESS_8290] enrollment at 12 sites (subjects/month/site)           0.[ADDRESS_8291]- approval study report MAY 2019
New text/timelines:
Revised/projected stud y milestones based on enrollment rates:
Study start date –First subject enrolled  NOV [ADDRESS_8292] enrollment at 12 sites (subjects/month/site) 0.[ADDRESS_8293]- approval study report JUL 2021
13.4 Amendment 6
13.4.1 Overview of changes
[IP_ADDRESS] Modification 1: addition of the TVU a s an approved method for Essure 
Confirmation Test
Rationale for change :In June 2015, TVU/HSG confirmation testing was approved for 
inclusion in the US IFU.
Sections affected by [CONTACT_8994]:
Synopsis
Section 5.1.1 Inclusion criteria
Section 6.3 Treatment assignment
Section [IP_ADDRESS] Eligibility  and Screening Visit ( -30 day s)
Section 8.6 Determination of sample size
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 68of 82
[IP_ADDRESS] Modification 2: definition of a successful Essure Confirmation test was 
clarified
Rationale for change : Language in the protocol was aligned with language in the IFU and 
the definition of a successful ECT was clarified.
Sections affected by [CONTACT_8994]:
Section 2 Study  objectives
[IP_ADDRESS] Modification 3 : modification of the Bayer template language regarding 
withdraw al criteria
Rationale for change : Since compliance with wearing the device is not an issue as it is 
permanent, this language is being removed.Sections affected by [CONTACT_8994]:
Section 5.2.1 Withdrawal
[IP_ADDRESS] Modification 4: information regarding the follow -up of adverse events 
was specified
Rationale for change : As subjects are consented for data collection until the [ADDRESS_8294], according to ICH -GCP no further stud y data can be collected beyond this point. 
However, serious adverse events and pregnancies are followed to resolution by  [CONTACT_8996]’s 
pharmac ovigilance department. The follow -up of non- serious AEs after 3 years is done 
according to the investigator’s medical judg ment and local standard of care.
Sections affected by [CONTACT_8994]:
Section [IP_ADDRESS] One -, Two -and Three -Year Post -EA Phone Call (± 28 days)
[IP_ADDRESS] Modification 5: NovaS ure device was included in the definition of the 
adverse device effect ,device deficiency, failure and malfunction
Rationale for change : Since NovaS ure is a medical device that will be used during the stud y, 
adverse device eff ects related to the use of NovaS ureas well as NovaSure device deficiency , 
failure and malfunction are possible.
Sections affected by [CONTACT_8997]:
Section [IP_ADDRESS].1.[ADDRESS_8295] (ADE)
Section [IP_ADDRESS].4 Device deficiency
Section [IP_ADDRESS].4.1 Device failure
Section [IP_ADDRESS].4.2 Device malfunction
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 69of 82
[IP_ADDRESS] Modification 6: definition of the unanticipated adverse device effect 
was modified for consistency
Rationale for change : This is the definition for unanticipated adverse device effect that is 
listed in the code of Federal Register (CFR).
Sections affected by [CONTACT_8994]:
Section [IP_ADDRESS].1.[ADDRESS_8296] (UADE)
[IP_ADDRESS] Modification 7: the definition of serious adverse event (SAE) was 
revised
Rationale for change : Clarification of SAE definition and to align with Bayer internal 
language for SAE definition.
Sections affected by [CONTACT_8994]:
Section [IP_ADDRESS].2 Serious adverse event (SAE)
[IP_ADDRESS] Modification 8: definition of [LOCATION_003]DE was clarified
Rationale for change : Since the protocol defines UADE and [LOCATION_003]DE separatel y but in the 
CFR the term UADE in fact refers to serious adverse events, a statement was added in the 
protocol to avoid confusion.
Sections affected by [CONTACT_8994]:
Section [IP_ADDRESS].2.[ADDRESS_8297] ([LOCATION_003]DE)
[IP_ADDRESS] Modification 9: perforations and potential allergy/hypersensitivity to 
Essure inserts were added to the Important Medical Events and events 
of special interest
Rationale for change: To collect information on perforations of the uterus, cervix or 
fallopi[INVESTIGATOR_8945] y subjects who develop potential allergy  or 
hypersensitivity  to Essure inse rts.
Sections affected by [CONTACT_8994]:
Section [IP_ADDRESS].[ADDRESS_8298]
[IP_ADDRESS] Modification 10: instructions for the Investigator to assess whether an 
AE is an unanticipated adverse device effect were removed
Rationale for change : Change was made in order to align with Bay er safety  reporting 
processes. Following the change in sponsor of this study  from Conceptus to Bay er, this 
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 70of 82
question is no longer required to be answered b y the investigator as this is an internal sponsor 
assessment.
Sections affected by [CONTACT_8994]:
Section [IP_ADDRESS] Assessments and documentation of adverse events
[IP_ADDRESS] Modification 11:addition of a new  section regarding device removal
Rationale for change : Addition of a device removal CRF to obtain more robust information 
regarding device removals.Sections affected by [CONTACT_8994]:
Section 7.4.2 Device removal
[IP_ADDRESS] Modification 12: minor edits and clarifications
Rationale for change : Minor edits and c larifications that were not previously  identified in 
protocol Amendment 5.Sections affected by [CONTACT_8994]:
Title page
Section [IP_ADDRESS] Reporting of serious adverse events
Section 14 Appendices
13.4.2 Changes to the protocol text
In this section, all affected protocol sections are detailed; the sequence of the sections follows the 
structure of the original protocol.  In the display of modifications, the “old text” refers to the 
protocol version preceding this amendment.  Deletions are crossed out in the “old text”.  Additions are underlined in the “new text”.  Corrections of typi[INVESTIGATOR_8940].   Specific changes to the text are described by [CONTACT_8982].
[IP_ADDRESS] Title page
Section revised per modification 12.
Old text:
Bayer HealthCare, LLC
[ADDRESS_8299]
Milpi[INVESTIGATOR_8946], CA [ZIP_CODE]
[LOCATION_003]
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 71of 82
New text:
Bayer HealthCare ,LLC
[ADDRESS_8300]
Whippany , NJ [ZIP_CODE]
[LOCATION_003]
[IP_ADDRESS] Synopsis
Section revised per modification 1.
Old text:
Diagnosis and main criteria for 
inclusion[…]
Subject has a successful Essure Confirmation Test withsatisfactory 
micro -insert location and fallopi[INVESTIGATOR_8947].
[…]
New text:
Diagnosis and main criteria for 
inclusion[…]
Subject has a successful Essure Confirmation Test showing bilateral
satisfactory micro -insert location (when using transvaginal ultrasound 
[TVU]) or both bilateral satisfactory location and tubal occlusion (when 
using a modified hysterosalpi[INVESTIGATOR_8913] [HSG]) documented in her 
subject record .
[…]
[IP_ADDRESS] Section 2 Study objectives
Section revised per modification 2.
Old text:
The objectives of this study are to:
Evaluate the contraceptive failure rate of Essure when NovaSure is performed following a 
successful Essure Confirmation Test, and
[…]
New text:
The objectives of this study are to:
Evaluate the contraceptive failure rate of Essure when NovaSure is performed following a 
successful Essure Confirmation Test*, and
[…]
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 72of 82
* Successful Essure Confirmation Test = satisfactory  bilateral micro -insert location and 
fallopi[INVESTIGATOR_8920], or satisfactory  oroptimal bilateral micro -insert 
location and retention in both tubal ostia when using transvaginal ultrasound (TVU) (i.e. the 
subject is able to rel y on Essure for contraception). Note: all subsequent descriptions of 
"successful" Essure confirmation test r efer to this definition.
[IP_ADDRESS] Section 5.1.1 Inclusion criteria
Section revised per modification 1.
Old text:
[…]
3.Subject has a successful Essure Confirmation Test with satisfactory  micro- insert 
location and fallopi[INVESTIGATOR_8948]
[…]
New text:
[…]
3. Subject has a successful Essure Confirmation Test showing bilateral satisfactory  
micro- insert location (when using transvaginal ultrasound [TVU]) or both bilateral 
satisfactory  insert location and tubal occlusion (when using a modified 
hysterosalpi[INVESTIGATOR_8913] [HSG]) documented in her subject record
[…]
[IP_ADDRESS] Section 5.2.1 Withdrawal
Section revised per modification 3.
Old text:
[…]
If, in the investigator's opi[INVESTIGATOR_1649], continuation of the study  would be harmful to the 
subject's well -being
Subjects may be withdrawn from the stud y for the following reasons:
At the specific request of the sponsor and in liaison with the investigator (e.g. obvious 
non-compliance, safet y concerns).
Subjects may  be terminated from the study  by [CONTACT_737].  Reasons for termination of a 
subject from the stud y may include, but are not limited to, the following:
[…]
New text:
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 73of 82
[…]
If, in the investigator's opi[INVESTIGATOR_1649], continuation of the study  would be harmful to the 
subject's well -being
Subjects may  be terminated from the study  by [CONTACT_737].  Reasons for termination of a 
subject from the stud y may include, but are not limited to, the following:
[…]
[IP_ADDRESS] Section 6.3 Treatment assignment
Section revised per modification 1.
Old text:
[…]
A subject may  not be enrolled in the study  until she has an Essure confirmation test done that 
documents bilateral satisfactory  device location and fallopi[INVESTIGATOR_8941].  If subject has 
had Essure placement but she does not have an Essure Confirmation Test that documents 
bilateral satisfactory  device location and fallopi[INVESTIGATOR_8941], she may  repeat the Essure 
Confirmation Test.
New text:
[…]
A subject may  not be enrolled in the study  until she has a successful Essure confirmation test 
done that documents bilateral satisfactory  device location and fallopi[INVESTIGATOR_8949] -insert location noted on TVU .  If subject has had 
Essure placement but she does not have an Essure Confirmation Test that documents bilateral 
satisfactory  device location and fallopi[INVESTIGATOR_8950]- insert location on TVU , she may  repeat the E ssure Confirmation Test.
[IP_ADDRESS] Section [IP_ADDRESS] Eligibility and Screening Visit (-30 days)
Section revised per modification 1.
Old text:
[…]
Inform the subject of the Essure -NovaSure PAS.  Subject will not enroll in the study  
until she has an Essure confirmation test that documents bilateral satisfactory  device 
location and fallopi[INVESTIGATOR_8941].  If subject has had Essure placement but she 
does not have an Essure Confirmation Test that documents bilateral satisfactory  device 
location and fallopi[INVESTIGATOR_8951], she may  repeat the Essure Confirmation Test.
[…]
New text:
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 74of 82
[…]
Inform the subject of the Essure -NovaSure PAS.  Subject will not enroll in the study  
until she has a successful Essure confirmation test that documents bilateral satisfactory  
device location and fallopi[INVESTIGATOR_8929]- insert location noted on TVU .  If subject has had Essure placement but she does 
not have an Essure Confirmation Test that documents bilateral satisfactory device 
location and fallopi[INVESTIGATOR_8952] -insert 
location on TVU , she may  repeat the Essure Confirmation Test.
[…]
[IP_ADDRESS] Section [IP_ADDRESS] One -, Two -and Three-Year Post-EA Phone Call (± 28 
days)
Section revised per modification 4.
Old text:
[…]
The [ADDRESS_8301] will be followed until 
event resolution. If a pregnancy  or adverse event was previousl y reported but event is not 
resolved during the 3- year phone call, event will be followed until resolution.  If no adverse 
events or pregnancies are reported, the Stud y Completion or Earl y Termination CRF will be 
completed after the 3 -year phone call.
New text:
[…]The [ADDRESS_8302] will be 
followed by  [CONTACT_456]’s pharmacovigilance department until even t resolution or 
stabilization . If a pregnancy  or serious adverse event was previousl y reported but the event is 
not resolved during the 3 -year phone call, the event will be followed by [CONTACT_456]’s 
pharmacovigilance department until resolution. In formatio n pertaining to these events will be 
collected and archived in the sponsor’s pharmacovigilance database.
[IP_ADDRESS] Section [IP_ADDRESS].1.[ADDRESS_8303] (ADE)
Section revised per modification 5.
Old text:
An AE related to the use of Essure, including AEs resulting from insufficient or inadequate 
instructions for use, deploy ment, implant (placement), installation or operation or any  
malfunction of the investigational medical device, use error or from intentional misuse of the 
medical device.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 75of 82
New text:
An AE related to the use of Essure or NovaS ure, including AEs resulting from insufficient or 
inadequate instructions for use, deplo yment, implant (placement), installation or operation or 
any malfunction of the investigational medical device, use error or from intentional misuse of 
the medical device.
[IP_ADDRESS] Section [IP_ADDRESS].1.[ADDRESS_8304] (UADE)
Section revised per modification 6.
Old text:
An AE is considered unanticipated if by  [CONTACT_5942], incidence, severit y or outcome it has not 
been ident ified in the IFU.
New text:
A serious adverse effect is considered unanticipated if by  [CONTACT_5942], incidence, severity  or 
outcome it has not been identified in the IFU.
[IP_ADDRESS] Section [IP_ADDRESS].2 Serious adverse event (SAE)
Section revised per modification 7.
Old text:
An SAE is classified as any untoward medical occurrence but is not related to a medical device 
that, meets any  of the following criteria:
1.Led to death
2.Led to a serious deterioration in the health of the subject that:
oresulted in a life -threatening il lness or injury
oresulted in a permanent impairment of a bod y structure or bod y function
orequired hospi[INVESTIGATOR_8943] a medical or surgical intervention to prevent permanent impairment 
to body  structure or function
Note :  For the purposes of this protocol, ectopic pregnancy  and spontaneous abortion are 
alway s considered as important events and therefore reported as SAEs.
New text:
An SAE is classified as any untoward medical occurrence that, at an y dose, me ets an y of the 
following criteria (a –g):
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 76of 82
a.Results in death
b.Is life -threatening
The term ‘life -threatening’ in the definition refers to an event in which the subject was 
at risk of death at the time of the event, it does not refer to an event which 
hypothe tically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081] 
A hospi[INVESTIGATOR_8953]:
-The admission results in a hospi[INVESTIGATOR_8954] 12 hours
- The admission is pre- planned
(e.g. elective or scheduled surgery  arranged prior to the start of the study ; 
admission is part of the study  procedures as described in Section 7.1.2)
-The admission is not associated with an AE 
(e.g. social hospi[INVESTIGATOR_8933]).
However, it should be noted that invasive treatment during an y hospi[INVESTIGATOR_8955] ‘medicall y important’ and as such may be reportable as an SAE 
dependent on clinical judgment.  In addition, where local regulatory  authorities 
specificall y require a more stringent definition, the local regulation takes precedence.
d.Results in persistent or significant disability  / incapacity
Disability  means a substantial disruption of a person’s ability  to conduct normal life’s 
functions.
e.Is a congenital anomal y / birth defect
f.Is another serious or important medical event as judged b y the investigator 
g.Requires intervention to prevent permanent impairment of a bod y function /damage , to 
a body  structure
Note :  For the purposes of this protocol, ectopic pregnancy  and spontaneous abortion are 
alway s considered as important events and therefore reported as SAEs.
[IP_ADDRESS] Section [IP_ADDRESS].2.[ADDRESS_8305] ([LOCATION_003]DE)
Section revised per modification 8.
Old text:
An unanticipated serious adverse device effect ([LOCATION_003]DE) is an y serious adverse effect on 
health or safety  or any  life-threatening problem or death caused by , or associated w ith, a 
device, if that effect, problem, or death was not previously  identified in nature, severity , or 
degree of incidence in the investigational plan or application (including supplementary  plan or 
application), or an y other unanticipated serious problem associated with a device that relates 
to the rights, safet y, or welfare of subjects.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 77of 82
New text:
An unanticipated serious adverse device effect ([LOCATION_003]DE) is an y serious adverse effect on 
health or safety  or any  life-threatening problem or death caused by , or a ssociated with, a 
device, if that effect, problem, or death was not previously  identified in nature, severity , or 
degree of incidence in the investigational plan or application (including supplementary  plan or 
application), or an y other unanticipated serio us problem associated with a device that relates 
to the rights, safet y, or welfare of subjects. This is the same definition provided in the UADE 
Section [IP_ADDRESS].1.2. This has been corrected above in the UADE definition. However, as both 
terms have been use d at various timepoints in this protocol, the definition is maintained here.
[IP_ADDRESS] Section [IP_ADDRESS].4 Device deficiency
Section revised per modification 5.
Old text:
Inadequacy  of Essure related to its identity , quality , durability , reliability , safet y or 
perfor mance, such as malfunction, misuse or use error and inadequate labeling.
New text:
Inadequacy  of Essure or Novasure related to its identity , qualit y, durability, reliability, safet y 
or performance, such as malfunction, misuse or use error and inadequate la beling.
[IP_ADDRESS] Section [IP_ADDRESS].4.1 Device failure
Section revised per modification 5.Old text:
Failure of Essure to perform or function as intended, including an y deviations from the 
performance specifications or intended use (e.g., pregnancy when micro -insert properl y 
located and fallopi[INVESTIGATOR_8935]; continued menorrhagia despi[INVESTIGATOR_040] a completed endometrial 
ablation procedure).  For the purposes of this study, a pregnancy  that occurs in a subject told 
to rely  on a commercially  available Essure device for contr aception is a device failure.
New text:
Failure of Essure or Novasure to perform or function as intended, including an y deviations 
from the performance specifications or intended use (e.g., pregnancy  when micro -insert 
properl y located and fallopi[INVESTIGATOR_8935]; continued menorrhagia despi[INVESTIGATOR_040] a completed 
endometrial ablation procedure).  For the purposes of this study , a pregnancy  that occurs in a 
subject told to rely  on a commercially  available Essure device for contraception is a device 
failure. For the purposes of this protocol, persistence or recurrence of heavy menstrual 
bleeding will be considered device failures for the Novasure device.
[IP_ADDRESS] Section [IP_ADDRESS].4.2 Device malfunction
Section revised per modification 5.
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 78of 82
Old text:
Failure of Essure to meet its performance specifications or otherwise perform as intended 
when used in accordance with the IFU (e.g., difficulties with deploy ment or detachment of 
micro-insert; device difficulties when conducting endometrial ablation).
New text:
Failure of Essure or Novasure to meet its performance specifications or otherwise perfor m as 
intended when used in accordance with the IFU (e.g., difficulties with deploy ment or 
detachment of micro -insert; device difficulties when conducting endometrial ablation).
[IP_ADDRESS] Section [IP_ADDRESS].[ADDRESS_8306]
Section revised per modification 9.
Old text:
[…]
Upper genital tract infections (for example: endometritis, salpi[INVESTIGATOR_8936] -oophoritis, 
salpi[INVESTIGATOR_8937]).
Expulsion or migration of Essure inserts.
New text:
[…]
Perforations of the uterus, cervix or fallopi[INVESTIGATOR_2134].
Upper genital tract infections (for example: endometritis, salpi[INVESTIGATOR_8936]- oophoritis, 
salpi[INVESTIGATOR_8937]).
Expulsion or migration of Essure inserts.
Potential allergy /hypersensitivity  to Essure inserts (for example: itch [pr uritus], rash, 
hives [urticaria ], facial edema, an gioedema, allergy  to metals). 
[IP_ADDRESS] Section [IP_ADDRESS] Assessments and documentation of adverse events
Section revised per modification 10.
Old text:
[…]
Investigators must document all device failures, malfunctions and use errors, including the 
assessment of whether the event is considered an incident (ADE) using the Device Malfunction and Failure CRF.
Investigator must determine whether adverse event is an unanticipated adverse device effect; 
if so, it must be reported as required b y Section [IP_ADDRESS].
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 79of 82
Because an approved device will be used for the placement procedure, an y device 
malfunctions will be reported to the sponsor’s Product Surveillance department.  Device 
malfunctions will not be anal yzed as part of this study  as the placement procedure and device 
are not being evaluated.
New text:
[…]
Investigators must document all device failures, malfunctions and use errors, including the 
assessment of whether the event is considered an incident (ADE) using the Device Malfunction and Failure CRF.
Because an approv ed device will be used for the placement procedure, an y device 
malfunctions will be reported to the sponsor’s Product Surveillance department.  Device 
malfunctions will not be anal yzed as part of this study  as the placement procedure and device s
are not be ing evaluated.
[IP_ADDRESS] Section [IP_ADDRESS] Reporting of serious adverse events
Section revised per modification 12.
Old text:
Investigator’s notification of the sponsor
[…]
All SAEs and incidents ( ADEs )occurring during the observation period defined in Section 
[IP_ADDRESS] must immediately  (within 24 hours of the investigator’s awareness) be reported to the 
sponsor. An SAE form must also be completed within 24 hours of the investigator awareness 
and forwarded to the sponsor’s designated recipi[INVESTIGATOR_841].  […]
Sponsor’s notifica tion of the investigational site
[…]
If the adverse event is also an unanticipated adverse device effect, the investigator must report 
it to the sponsor within 3 working days after the investigator becomes aware of the event.  
The investigator will send to the sponsor all pertinent paperwork (discharge summaries, office 
notes, etc.) within 5 working days.  
[…]
New text:
Investigator’s notification of the sponsor
[…]
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 80of 82
All SAEs and S ADEs occurring during the observation period defined in Section [IP_ADDRESS] must 
immediately  (within 24 hours of the investigator’s awareness) be reported to the sponsor. An 
SAE form must also be completed within 24 hours of the investigator awareness and 
forwarded to the sponsor’s designated recipi[INVESTIGATOR_841].  
[…]
Sponsor’s notification of the investigational site
[…]
If the adverse event is the result of an unanticipated adverse device effect, the investigator 
must report it to the sponsor within 3 working days aft er the investigator becomes aware of 
the event.  The investigator will send to the sponsor all pertinent paperwork (discharge 
summaries, office notes, etc.) within 5 working day s.  
[…]
[IP_ADDRESS] Section 7.4 .2 Device removal
Section added per modification 11.
Old t ext:
Not applicableAdded text:
Each time a removal procedure is performed, additional information will be collected about 
the circumstances surrounding the removal (reason for removal, procedure details, any  energy  
sources used, vasoconstrictive agent use d, imaging to assist with confirming the location of 
the insert, and the location and status of the device removed).
Note that the Section numbering inside the Section 7.4 has changed due to this modification.
[IP_ADDRESS] Section 8.6 Determination of sample size
Section revised per modification 1.Old text:
[…]Assumptions
The following assumptions were used to calculate the PAS sample size and power for the 1 -
and 3- year h ypothesis:
Participants in this PAS are women who have undergone the Essure procedure 
followed b y a successful Essure Confirmation Test showing satisfactory micro -insert 
location and bilateral tubal occlusion;
[…]
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 81of 82
New text:
[…]
Assumptions
The following assumptions were used to calculate the PAS sample size and power for the 1 -
and 3- year h ypothesis:
Participants in this PAS are women who have undergone the Essure procedure 
followed b y a successful Essure Confirmation Test showing satisfactory micro -insert 
location and bilateral tubal occlusion onHSG OR optimal or satisfa ctory  micro insert 
location on TVU ;
[…]
[IP_ADDRESS] Section 14 Appendices
Section revised per modification 12.
Old text:
Appendices A -D were to be distributed to all sites with the protocol and were not attached to 
this amendment to reduce redundancy .  
Appendix E: Detailed Study Timelines
Revised/projected stud y milestones based on enrollment rates:
[…]
New text:
All appendices from prior protocol amendments (Essure IFU, NovaSure Instructions for Use 
and Controlled Operator’s Manual, Case Report Form and the Inform ed Consent) have been 
distributed to the sites with  previous protocol versions and are therefore not attached here to 
avoid redundancy .  
15.  Detailed Study Timelines
Revised/projected stud y milestones based on enrollment rates:
[…]
Integrated Clinical Study Protocol
No.  [ZIP_CODE]
12JUL 2016 Version 6.0 Page: 82of 82
14. Appendices -amended
All appendices from prior protocol amendments ( Essure IFU, NovaSure Instructions for Use 
and Controlled Operator’s Manual, Case Report Form and the Informed Consent) have been 
distributed to thesites with previous protocol versions and are theref ore not attached here to 
avoid redundancy .55  
15. Detailed Study Timelines
Revised/projected stud y milestones based on enrollment rates :
Study start date –First subject enrolled  NOV [ADDRESS_8307] enrollment at 12 sites (subjects/month/site)           0.[ADDRESS_8308]- approval study report JUL 2021
                                                
55Text modified per Amendment 6.